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Summary (English)
The use of automated image analysis of microscopy images is increasing to enable high throughput
approaches and unbiased analysis of the increasingly large data sets produced. This thesis investi-
gates the use of automated image analysis to quantify peptide analogue distribution in mouse brain
tissue. The main group of peptides included in this work was glucagon-like peptide 1 receptors agonists
(GLP-1RA) used for treatment in diabetes and obesity. Two main image modalities have been applied
for image acquisition; Light Sheet Fluorescence Microscopy (LSFM), and slide scanner images of 2D
histology sections. The work demonstrates the use of automated image analysis based on image regis-
tration to quantify LSFM data of the peptide brain distribution following peripheral administration.
The methodology was expanded during the PhD work to also include study of receptor mapping and
brain activation. The automated analysis was enabled by integration with a digital multimodality
brain atlas from the Allen Institute of Brain Science (AIBS). The work showed that GLP-1RAs ac-
cessed multiple brain regions mainly in the hypothalamus and hindbrain and led to increased brain
activation in regions related to decreased food intake. The developed integrated brain atlas provides
a novel analysis approach for LSFM data to aid researchers understand the complex brain biology
related to development of pharmaceuticals with brain mode of action.
ii
Summary (Danish)
Brugen af automatiseret billedanalyse af mikroskopi-billeder stiger for at muliggøre analyse af store
datasæt. I denne afhandling undersøges muligheden for at benytte automatiseret billedanalyse til at
kvantificere hjernefordelingen af peptidanaloger i mus. Hovedgruppen af peptider undersøgt i dette
arbejde var glucagon-like peptide 1 receptors agonister (GLP-1RAs) som bruges i behandling af di-
abetes og fedme. To typer af mikroskoper blev benyttet til dataopsamling; Light Sheet Fluorescence
Microscopy (LSFM), og slide scanner billeder af 2D histologi sections. Arbejdet demonstrerer brugen
af automatiseret billedanalyse til at kvantificere LSFM data af peptidfordeling i hjernen efter perifær
injektion. I løbet af PhD projektet blev metoderne udvidet til også at tillade studie af receptorforde-
ling og hjerneaktivitet. Den automatiserede analyse bygger på integration med et multimodalt digitalt
hjerneatlas fra Allen Institute of Brain Science (AIBS). Projektet viste at GLP-1RAs har adgang til
adskillige hjerneområder primært i hypothalamus og baghjernen, og at de medførte øget hjerneaktivitet
i områder relateret til nedsat fødeindtag. Det udviklede integrarede hjerneatlas muliggør en ny type af
analyse af LSFM data som kan hjælpe forskere med at forstå den komplekse hjernebiologi relateret til
udvikling af medicin med direkte effekter i hjernen.
iv
Preface
This thesis was prepared at the Image Analysis and Computer Graphics Section at Department of
Applied Mathematical And Computer Science at the Technical University of Denmark (DTU) in col-
laboration with the Histology and Imaging department, Global Research, Novo Nordisk A/S. The thesis
was done in fulfillment of the requirements for obtaining a doctor of philosophy (PhD) within the topic
of image analysis. The work presented in the thesis was financed by Innovation Fund Denmark and
Novo Nordisk A/S. The thesis presents research concerning automated image analysis of microscopy
images of biological tissue, mainly describing brain distribution, receptor localization, brain activation
and brain connectivity in connection with peptides involved in regulation of appetite and food intake.
The first part of the thesis presents the theoretical background for pharmaceuticals with brain mode of
action, together with background on the applied instruments and analysis methods. The second part
presents the major findings and put these into the context of the presented methodologies. Finally,
the thesis is concluded, and followed by five manuscripts that were prepared during the PhD project.
The project has been supervised by associate professor Anders Bjorholm Dahl and research scientist
Anna Secher, and co-supervised by Professor Knut Conradsen and research scientist Jacob Hecksher-
Sørensen. The research has been carried out at DTU and Novo Nordisk A/S. External research was
conducted at Novo Nordisk Research Center Seattle in combination with visits to the Allen Institute
of Brain Science.
Lyngby, 31-August-2017
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Chapter 1
Introduction
The work in this industrial PhD project was funded in part by the Innovation Fund Denmark. The
activities within the fund aim to strengthen the collaboration between academia and industry. The
project was performed in collaboration with Novo Nordisk A/S, a pharmaceutical company with mar-
keted treatment options within diabetes, hemophilia, growth hormone therapy, hormone replacement
therapy, and obesity. Over the last three decades, mean body-mass index (BMI) has increased by 0.4
kg/m2 per decade worldwide [FSC+11], and in the US the prevalence of obesity was 35.5% among
adult men and 35.8% among adult women in 2009-2010 [FCKO12]. Further, the prevalence of the
extreme weight categories (BMI>40 and >50) increased more than 70% from 2000-2010 [SH13]. The
dramatic increase in the prevalence of obese and overweight individuals has intensified interest in obe-
sity as a major health problem. For the individual the consequence of obesity is an increased risk of
acquiring metabolic diseases like type II diabetes and cardiovascular disease [C+09]; and for society the
economic burden is pushing the already stretched healthcare budgets [CM12]. Thus the development
of treatment options for obesity has long been in focus for many in the pharmaceutical industry, but
so far very few companies have been successful. One reason for this is that the so far most effective
treatment options primarily function through the brain. The brain has limited access from the periph-
ery were pharmaceutical compounds are often delivered, and also potential for unwanted side effects.
For pharmaceutical compounds to work directly in the brain they must be able to access the brain
in select regions or by crossing the blood brain barrier (BBB). Thus the future design of treatment
options will benefit from a better understanding on how and where pharmaceutical compounds enter
the brain. Research is ongoing regarding how the pharmaceutical compounds or naturally occurring
peptides enters the brain from the blood [LLL+13], [PK01]], but the brain distribution of pharmaceu-
ticals are still poorly understood due to lack of good experimental methods.
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A technology which might overcome these limitations is LSFM which is a non-destructive, ex vivo
method to produce well-registered optical sections suitable for 3D reconstruction [DLS+07]. This al-
lows researchers to visualize the distribution of fluorescently labelled peptides in the whole mouse
brain. Recently, LSFM has further been used to evaluate whole mouse brain activation [RAK+16]
which is another important aspect when researching the effect of pharmaceuticals. However, as the
image detail is approaching single cell resolution the data sets become enormous and high throughput
quantitative and unbiased analysis is only possible using appropriate software programs. In order to
accelerate the speed and quality of the results obtained from LSFM it will be important to develop
computer algorithms to assist in the analysis. The development of such algorithms is the main purpose
of this PhD project. The chosen analysis approach has been focused on computational atlases which are
increasing in neuro-imaging and employed in various imaging modalities both in humans and animal
models [FEB+11], [LHA+07]. Digital atlases are produced by computation of averages of ensembles of
segmented images after image registration [WZW04],[VL09]]. A new image can then be analysed by
image registration to the atlas (average image) and superimposition of the segmented structures from
the atlas.
An important family of obesity treatment options is modified peptides based on the natural occurring
glucagon-like peptide 1 (GLP-1) molecule released in the intestine in response to food intake, and a
neurotransmitter produced in the hindbrain. It has been shown that GLP-1RAs act on peripheral
organs but also target GLP-1 receptors (GLP-1R) in the brain, and that this contributes in large part
to the weight loss effect [SJB+14], [SGAS+14]. Another naturally occurring peptide is leptin, which is
released from fat tissue and provides information on body energy status to the brain by activating the
long form of its receptor (LepRb). Leptin is thus also part of the system that controls food intake and
energy homeostasis [FH98]. The automated analysis approach developed during this PhD project was
used to investigate brain actions of GLP-1RAs and leptin when administered peripherally to mimic
treatment of patients.
1.1 Laboratory Work
A large amount of experimental and laboratory work have been performed during the course of the
PhD project. The work has mostly concerned tissue preparation and image acquisition using LSFM.
The process has been important as variations in the laboratory work directly shows up in the images
as different artifacts which is a challenge to the automated quantitative analysis. As a data analyst it
is in general important to be somewhat part of the experiments in order to understand and optimize
the process. The following paragraphs outline the laboratory work performed in the project. Tissue
samples of the mouse brain have been the main focus throughout the thesis. The samples have been
imaged either in 3D using LSFM, or as 2D sections using classical histology. Both image platforms
are used with ex vivo tissue samples that require preparation prior to image acquisition. Paper A,
C, D, and E include whole brain data obtained with LSFM. The laboratory work included tissue
extraction, fixation, clearing, mounting and setting up the LSFM acquisition sequence. An important
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learning was that variations in the clearing protocol led to large differences in the amount of tissue
deformation observed in the brain samples, which again was an important factor when evaluating the
image segmentation quality. The images in Figure 1.1a shows some of the laboratory work performed
with LSFM imaging. Paper A and B include imaging and analysis of 2D histology sections of paraffin
embedded brain samples. In the acquired images the largest artifacts were related to physical damage
during the tissue cutting. Another important learning was that the tissue cutting rarely was performed
at the orthogonal angles otherwise strived for. This was important when performing image registration
to 2D atlases often produced with orthogonal angels, e.g. coronal sections.
1.2 Objectives
The main objective of this thesis was to develop algorithms for automated quantification of whole
mouse brain LSFM data. The developed computational approach should allow high throughput quan-
tification to be accomplished. Figure 1.1b-d shows an example of LSFM data where segmentation of
brain regions allows quantification of the fluorescent signal.
The aim of the brain atlas to be constructed based on images from LSFM was to provide a valuable
resource for current and future research investigating peptide access to the mouse brain. During the
project the objective broadened from peptide access to further include investigation of brain activation,
peptide receptor mapping, and to some extend brain connectivity.
The conducted experiments have focused on GLP-1RAs and leptin, and their application as anti-obesity
treatment options.
4 Introduction
Figure 1.1: (a) Left: cleared mouse brain. Middle: mounting of brain sample. Right: Mounted
brain sample inside imaging chamber scanned with a laser light sheet. (b) Examples of
2D coronal projections from the 3D LSFM acquisition. Manual segmentation of brain
regions would require going through many such images and drawing brain structures by
hand. (c) Example of an annotated brain structure in 3D. (d) Example of multiple brain
region annotations applied in 3D. These annotations were obtained using a digital brain
atlas to automate the analysis process.
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1.3 Thesis Overview
The thesis consists of two parts followed by a part with the contributions, i.e. the manuscripts which
represent the scientific findings in the thesis. Part I presents the methodology and theoretical back-
ground concerning peptides, the utilized microscopy systems, image analysis, and statistical framework.
Part II of the thesis explains how the methodology has been applied to obtain the results in the con-
tributions. Part II should be seen as the link between the methodology and the contributions. The
thesis is concluded as the last chapter in Part II. The contributions are included in Part III in their
current layout.
6 Introduction
Part I
Methodology

Chapter 2
Central regulation of appetite
This section describes central regulation of appetite in connection with peptide hormones. This is a
vast topic and the focus will be limited to a subset of systems most relevant for the work conducted in
this PhD project. This includes two peptide hormones; GLP-1 and leptin, which are hormones both
part of the exchange of information between the brain and other organ systems. This is followed by
a description of brain access looking at how these peptides may reach the brain, and a description of
what brain activation might occur as response to the peptides entering the brain.
2.1 Peptide hormones
Communication between the brain and other organ systems are important in order to maintain energy
homeostasis. This communication can take place through electric signaling conducted through nerves
such as the vagus nerve which provide connections between the gastrointestinal (GI) tract and the
brain. The communication can also be facilitated through hormones released from specialized cells to
travel through the blood to the brain (Fig 2.1). Two such peptide hormones involved in the control
of food intake are GLP-1 and leptin. The pharmaceutical industry has attempted to create treatment
options for diabetes and obesity based on these natural occurring peptides by developing agonists with
improved pharmacokinetics. The efforts have been successful concerning GLP-1 where several marked
treatments are available for type II diabetes and one for obesity, namely liraglutide marked under the
brand name Saxenda. Treatment options based on leptin have not succeeded.
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Figure 2.1: Sketch showing examples of how the mouse brain receives information from the periphery.
Leptin is released from adipose tissue into the vascular system to signal the level of energy
storage. Satiety signals from the GI tract are transmitted through the vagus nerve and
through the vascular system. Important brain regions receiving the information are
arcuate nucleus (ARH) in the hypothalamus, and nucleus of the solitary tract (NTS) in
hindbrain.
2.1.1 GLP-1
GLP-1 is an incretin hormone released from gut endocrine L-cells following meal ingestion. GLP-1 has
an important role in regulating insulin release by activation of the GLP-1R expressed on pancreatic
beta cells thereby normalizing blood glucose levels [ZMMH02]. GLP-1 is also produced and released
as a neurotransmitter from hindbrain neurons [TC15]. The GLP-1R distribution is abundant in the
brain [MLS99], [CRH+15], and these receptors can potentially be activated both by the endogenous
GLP-1 produced in the brain and/or by circulating GLP-1 from the periphery. The fact that GLP-
1Rs are expressed in many brain regions indicate diverse actions of this peptide, many of which has
been discussed before [VL10], [DCZ+03]. Following peripheral administration longer acting GLP-
1RAs affect appetite [VCSJ+14] and lower bodyweight [OGGC+16] likely through mechanisms in the
brain [SJB+14], [SGAS+14]. Liraglutide is a GLP-1RA approved and widely used for the treatment
of diabetes [NHF+06], and is also approved as a treatment option for weight management, reducing
appetite and body weight following peripheral once-daily administration [OGGC+16].
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2.1.2 Leptin
Leptin is a peptide hormone encoded by the ob gene expressed mainly in adipose tissue. Secretion of
leptin from adipocytes provides information on body energy status to the brain by activating LepRb
[BSD+03]. Leptin has been showed to control food intake and energy homeostasis [FH98]. Like GLP-
1R the LepRb is abundantly expressed throughout the mouse brain. The highest concentrations of
LepRb neurons are found in the hypothalamus, such as the ventral premamillary (PMv), Dorsomedial
nucleus of the hypothalamus (DMH), and ARH [PLJM11] which are important centers for regulating
feeding [EES99]. Besides controlling energy homeostasis leptin is also involved in regulating body
temperature and supporting reproductive function [MMLL09]. The ob gene is needed to produce
functional leptin, and the db gene is needed for the cells to produce LepRb. Recessive mutations
in either the ob or db genes result in obesity and diabetes in a syndrome resembling morbid human
obesity [Col78], [CCT+96]. Without a functioning leptin system ob/ob and db/db mice models obtain
identical phenotypes, each weighing three times more than normal mice. Leptin replacement therapy
in humans with leptin deficiency caused by genetic mutation can restore a lean phenotype. However,
when the obesity is instead caused by increased energy intake the state is related to hyperleptinemia
and leptin tolerance or leptin resistance [BM09].
2.1.3 Brain access
Molecular traffic between the periphery and the central nervous system (CNS), as is needed to deliver
potential therapeutics to specific areas of the brain, is restricted by brain barriers. The most well-known
barriers are the BBB and the blood-cerebrospinal fluid (CSF) barrier. As an example the hypothalamus
is restricted by a BBB composed of tight junctions between endothelial cells lining brain microvessels
[NBF+11]. However, circumventricular organs (CVOs) containing fenestrated capillaries allowing free
access of blood borne molecules exists in the brain. Examples of CVOs include area postrema (AP),
median eminence (ME), vascular organ of the lamina terminalis (OV), and subfornical organ (SFO).
Another example of structures with fenestrated capillaries are the choroid plexus (chpl) located in the
ventricular system, e.g. the fourth (V4) and lateral (VL) ventricle. Recent literature suggests the
ME to be a site for uptake of peripheral peptides such as leptin from the blood [SLL+13], [BDL+14]
and this could be extended to include GLP-1RAs. Indeed nearly all CVOs including the ME have a
high expression of GLP-1R suggesting interaction of peripheral GLP-1 in these regions. In this PhD
work we have utilized fluorescently labelled peptides to investigate brain access of different peptides.
The labelled peptides were injected either subcutaneous or intravenous and allowed to distribute for
a number of hours having the possibility to access the brain. The mice were then euthanized and the
brains were extracted for LSFM imaging.
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2.1.4 Brain activation
If the circulating peptides access the brain and bind their receptor, the targeted cells may be activated.
The binding of a receptor may initialize several downstream signals within the cells. As an example
downstream Stat3 signaling mediates the effects of leptin on melanocortin production and body energy
homeostasis [BSD+03]. In the process of signaling Stat3 becomes phosphorylated and thus referred to
as pStat3. During the work in this PhD thesis pStat3 signaling were imaged by using whole mount
staining [RWS+14] with a primary pStat3 antibody. However, it should be noted that pStat3 signaling
is not leptin receptor specific and may also be initiated by other molecules. Likewise, pStat3 is not the
only mediator of leptin action [RLM08].
The study of direct brain activation from GLP-1R is more difficult as no direct marker is available. An
alternative is to use a broad activation marker such as c-Fos, which is part of the family of immediate
early genes (IEGs) whose expression levels reflect recent changes in neuronal activity [RAK+16]. IEGs
have low temporal resolution, and up-regulation of their expression usually lags neuronal stimulation
by 30 minutes. Their expression can outlast the end of activity by several hours. During the work in
this PhD thesis c-Fos was used to investigate the brain activation following peripheral administration
of GLP-1RAs. In the discussion of brain activation it is important to note that receptor binding by
a ligand can not always be visualized by c-Fos expression. Also the receptor binding may can cause
inhibition, e.g. lower or no c-Fos activation compared to baseline activity level.
Neurons project widely in the brain to convey information from one region to the other. Thus direct
activation in one brain region may lead to secondary activation in other brain regions forming complex
neuro-circuits. A way to study brain connectivity is using recombinant adeno-associated virus (AAV),
expressing EGFP to perform anterograde tracing of axonal projections [CDdLS98]. Such analysis
was performed in large scale by AIBS to create a mesoscale connectome of the adult mouse brain
[OHN+14]. These connectivity maps have been downloaded and used to add context to some of the
LSFM experiments performed regarding brain activation.
Chapter 3
Imaging systems
This chapter presents the imaging systems used in this PhD thesis. LSFM has been used to acquire 3D
data of the whole mouse brain, while a slide scanner has been used to acquire 2D images of histology
sections. The main focus has been on LSFM, where much work has also gone into optimization of
tissue preparation and scan sequences. The slide scanner has been used with a standard setup.
3.1 LSFM
LSFM is a non-destructive method to produce well-registered optical sections suitable for 3D recon-
struction. The system provides high sensitivity, micrometer resolution, and short acquisition time
enabling imaging of a whole mouse brain in less than one hour [DLS+07]. LSFM belongs to the family
of light microscopes, hence the contrasts available for imaging are based on fluorescence properties
of the molecules in the sample. This also implies that samples must be chemically cleared prior to
imaging, to allow the light sheet to illuminate the sample with minimal scattering.
3.1.1 Microscope setup
The LSFM system used during this Phd work is seen in Figure 3.1a. A broad spectrum laser is led into
the microscope where a series of optical elements such as mirrors and lenses shape the laser beam into a
thin light sheet with a gaussian beam profile (Fig. 3.1b). Prior to beam shaping unwanted wavelengths
are filter away providing a specific excitation wavelength. The light sheet illuminates a sample located
inside a dibenzyl ether (DBE) filled imaging chamber and excites molecules in the sample. Photons
emitted from the sample in response to excitation are observed by a microscope zoom body. The
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emitted light is filtered providing a specific emission wavelength. A sCMOS camera produces digital
2D images of the sample. To acquire a 3D volume a step motor moves the sample in small increments
through the light sheet. The sequence can be repeated to acquire multiple contrasts of the same sample
using different filter settings.
Figure 3.1: (a) LSFM system used during the Phd work. The microscope is a Lavision II setup from
Lavision Biotec. A white light laser from NKT photonic delivers the laser which are
shaped into a light sheet and used to excite the sample positioned inside the imaging
chamber. Emitted light from the sample travels through a zoom body and images are
acquired with a Andor NEO sCMOS camera. (b) Illustration of a light sheet (green) which
illuminates a tissue sample (yellow). Image reproduced by permission from Lavision
Biotec.
3.1.2 Tissue preparation
To obtain transparent samples mice were euthanized by cardiac perfusion and the brain extracted.
Following extraction the tissue was fixed to avoid further degradation by enzymes and to avoid diffusion
of ligands from receptors. Depending on the desired contrast mechanism a whole brain staining protocol
was applied. In this thesis work the iDISCO protocol [RWS+14] was used. The final step in tissue
preparation was tissue clearing where a solvent-based approach was used to obtain cleared samples
when imaged in DBE [EBJ+12]. The tissue preparation often lead to artifacts in the imaged brain
seen as mechanical damage from tissue extraction, and shrinkage and deformation from fixation and
clearing. The process is summarized in Figure 3.2a-b.
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Figure 3.2: (a) Tissue preparation steps to obtain a mouse brain sample for LSFM imaging. ∗Whole
mount staining is not performed if the study involves flurescently labelled peptides. (b)
Cleared mouse brain (yellow). The cleared brain will become transparent when emerged
into a DBE filled imaging chamber.
3.1.3 Contrast mechanisms
As the name implies the contrast mechanisms of LSFM is based on fluorescence. Fluorescence is a
property of some molecules which enables them to take up energy from light at a specific wavelength
(excitation) and shortly after release energy in form of light at a slightly shifted wavelength (emission).
Excitation and emission wavelengths are specific for different molecules which are utilized during imag-
ing. Different molecules of normal human and animal tissue are fluorescent which is normally termed
auto-fluorescence. Auto-fluorescence has a broad excitation and emission spectrum, but is normally
most intense at lower wavelengths. During this Phd project the auto-fluorescence from brain tissue
was recorded and used for anatomical information (Fig 3.3). It was observed that different tissue
preparation protocols influenced the auto-fluorescence, especially the white matter of the brain. Also
regarding the white matter a discovery was made enabling a strong contrast in the white matter tracts
by the use of an emission filter and excitation filter with identical wavelengths. To study the brain dis-
tribution of peptides of interest a commercial fluorescent molecule with known spectra characteristics
was chemically attached to the peptide (Fig 3.3). A similar approach was used with whole mount IHC
staining where a commercial fluorescent molecule was attached to a secondary antibody which would
then bind to a primary antibody to detect an antigen of interest.
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Figure 3.3: Overview of the LSFM contrast mechanisms used during the Phd work. White arrows
indicate specific signals from commercial fluorescent molecules. Filter settings refer to
the settings of the LSFM microscope during data acquisition. Image examples are either
3D maximum intensity projections or 2D projections. Please note that the microscope
acquires light intensities, i.e. produces grayscale images. Color maps are applied for
visualization purposes only.
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3.2 Slide scanner
A slide scanner is a form of light microscope constructed such that many 2D slides with thin tissue
samples may be loaded into the scanner simultaneously. The slides are imaged one by one and saved
as digital files usually in a pyramid format enabling zoom up to 40X. Slide scanners are available for
both fluorescence and chromogene stained tissue samples. In this Phd work data was obtained using
chromogene stained tissue samples.
3.2.1 Tissue preparation
After tissue removal the first tissue preparation step was fixation performed to preserve structure.
The fixation will terminate cell metabolism, prevent enzymatic degradation, kill potential pathogenic
microorganisms, and fix lignads to receptors. Next, the tissue sample must be embedded in a medium
that allows it to be cut into thin sections. In the work of this thesis, sections were dehydrated and
embedded in paraffin. Lastly, the paraffin block containing the tissue is mounted in a microtome and
cut into thin slices and placed on glass slides before imaging.
3.2.2 Contrast mechanisms
Contrast dyes, such as e.g. hematoxylin will broadly stain cellular components of the tissue with gradu-
ated intensity. Specific stains will on the other hand only stain specific components of the tissue leaving
the rest of the tissue unstained. Examples of a specific staining techniques are immunohistochemical
staining (IHC) and in situ hybridization (ISH).
Neurons are the primary cell type of brain tissue. Neurons consist of a cell body from which an axon of
varying length transmit electronic signal from the neuron to other neurons. In the light microscope the
ribosomal content of the cell body appears as small bodies, called Nissl bodies, and these stain intensely
with basic contrast dyes [RP06]. This was utilized to obtain anatomical information from brain tissue
(Fig 3.4). IHC staining is based on reactions between antigens and antibodies. Antibodies, also called
immunoglobulins, are glycoproteins produced by the immune cells in response to foreign proteins called
antigens. A pair of antibodies and antigens will bind upon meeting. This specific binding may then be
examined in the microscope and thereby provide a specific staining of the antigen of interest [RP06]
(Fig 3.4). ISH is part of the family of hybridization techniques where single-stranded RNA or DNA
molecules interact with complementary nucleotide sequence, called a nucleotide probe. With ISH the
binding between probe and singled stranded RNA or DNA is performed within cells or tissues, such
as in thin histology sections. In this Phd work a recent developed commercial ISH platform based on
non-radioactive chromogene detection was used to detect mRNA [AZM+16], [WFS+12] (Fig 3.4).
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Figure 3.4: Overview of the histology contrast mechanisms used during the Phd work. For the IHC
example brown color show positive stained cells. With ISH the red dots show positive
stained cells. Details on the exact staining protocols such as information about antibodies,
RNA probes, etc. are provided in the individual papers.
Chapter 4
Image analysis
This chapter describes a number of subjects within automated image analysis. First, a digital brain
atlas is introduced, followed by a description of image registration used to align samples based on
the atlas. The next sections describe the methods applied to extract specific information from the
microscopy images, including spectral unmixing and image segmentation methods. A description of
the statistical methods applied in this thesis work is also provided, and lastly a description of an
alternative segmentation approach based on active appearance models (AAMs).
4.1 Digital brain atlas
Currently, no digital brain atlas is public available constructed from LSFM data. However, a high
quality atlas also based on auto-fluorescence is available from AIBS constructed from two-photon
microscopy images [OHN+14]. This atlas was used as basis for analysis of LSFM data.
4.1.1 AIBS atlas
The AIBS data portal holds many open access resources for brain research. Most data regarding the
mouse brain is aligned to the Common Coordinate Framework version 3 (CCFv3) reference space based
on a template brain constructed from 1675 specimens (Fig 4.1a). A number of resources are coupled
to this template brain such as detailed annotations, a histology based template, and a range of neural
connectivity maps (Fig. 4.1b-d). During the PhD project these data have been linked to LSFM as well
as 2D histology data.
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Figure 4.1: (a) CCFv3 template based on two-photon microscopy images from 1675 individual mouse
brains. (b) Detailed annotations constructed to fit the CCFv3 template. (c) Aligned
template re-constructed from 2D Nissl stained histology sections. (d) Neural connectivity
maps constructed from mouse brains after stereotactical injection of AVV to trace axons
projecting out from the injection site. Figure modified from [oBS17].
4.2 Image registration
To utilize the digital brain atlas a moving image (individual brain sample) IM (x) must be deformed
to fit a fixed image (atlas template) IF (x). The images have dimension d and are defined on their
own spatial domain: ΩF ⊂ Rd and ΩM ⊂ Rd , respectively. With LSFM d=3 and with histology
sections d=2. Image registration is now the problem of computing a transformation T (x) = x + u(x)
that makes IM (T (x)) spatially aligned with IF (x) [KS15] (Fig 4.2a). In the PhD work a global affine
coordinate transformation for initialization followed by non-rigid b-spline coordinate transformation
for local deformations was utilized. The underlying image is then deformed by manipulating a defined
mesh of control points based on the b-splines. The number of control points is important in regards to
regularization, i.e. how much deformation is allowed. Determining the right amount of regularization
is important as too much regularization will restrict the deformation not reaching the optimal solution,
while too little regularization will lead to unrealistic deformations in the image. A fast way to regularize
the deformation is to apply multi-level b-splines [SRQ+01] where the final local transformation is the
sum of the transformations at each level. To compute the most optimal transformation aligning IM (x)
to IF (x) a similarity measure is needed. The simplest similarity measure is sum of squared differences
(SSD) which works well in situations where the images originate from the same modality and contains
similar intensity distributions. A similarity measure which is applicable in a wider range of situations,
e.g. cross modality registrations, is mutual information (MI) [SHH99]. These similarity measures were
used for different registrations during this PhD work. To obtain the most optimal transformation
it is common to use an iterative optimization strategy such as gradient descent. The number of
iterations will influence the amount of deformation, with less iterations providing a higher degree of
regularization. In the work presented in this PhD thesis two libraries were utilized for computing and
applying transformations, namely Elastix [KSM+10], and IRTK [RSH+99], [SRQ+01].
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4.2.1 LSFM studies
To avoid cross-modality cross-subject registrations a LSFM template was constructed and aligned to
the AIBS atlas. This template was based on one representative mouse brain. Once constructed this
template was used to align other LSFM samples to the AIBS atlas. As mentioned in Section 3.1.2 a
number of tissue preparation steps are performed prior to LSFM acquisition. The preparation step
can cause large deformation of the tissue (Fig 4.2a). The tissue shrinkage was observed to be non-
uniform in different parts of the brain which meant that the standard approach of applying an affine
transformation to account for global deformation was not adequate in this situation. To mitigate
the effects of the non-uniform tissue shrinkage a registration model which allowed different degrees
of shrinkage in each of the larger brain structures was developed. In practice this was enabled by
performing a pre-segmentation to divide the brain into ten larger structures by image registration
with low regularization allowing large deformations. Next, an affine and b-spline transformation as
described in Section 4.2 was performed for the ten individual brain structures and combined to yield
the final registration result (Fig 4.2b).
Figure 4.2: (a) Example of acquired brain sample to be registered to the LSFM template of the
integrated brain atlas. (b) The result of aligning the sample to the LSFM template.
The registration was performed in separate parts to mitigate non-uniform deformations.
Separate affine and b-spline registration was performed for ten larger structures, here
visualized by the overlay colours in the lower part of the figure. (c) LSFM template to
which the brain sample was aligned. (d) Example of the registration performed for one
of the larger structures in the alignment between the brain sample and LSFM template.
Images are taken from the yellow structure shown in the lower part of (a)-(c).
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4.2.2 2D Histology studies
A number of challenges were encountered in the process of aligning 2D histology section to the histology-
based template of the AIBS atlas. An experiment was performed to determine what types of back-
ground stain were suitable to provide adequate contrast for registration. A Nissl counter stain was
found to be most similar to the AIBS atlas template, while a haematoxylin stain also provided much
of the contrast information needed (Fig. 4.3). The second challenge was that the tissue sections rarely
were cut at exact orthogonal angles, which otherwise are the standard of most atlas plates. If two
sections to be aligned are produced at different angles they will not contain the same anatomical in-
formation making the registration meaningless. To mitigate this challenge interpolated sections of the
3D AIBS atlas template were manually produced to match the cutting angles of the 2D nissl stained
sections prior to registration (Fig. 4.4).
Figure 4.3: Images to compare anatomical contrast information between nissl stain, haematoxylin, or
no staining, in relation to the AIBS atlas template. The acquired images were converted
to gray scale images to be more comparable to the atlas.
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Figure 4.4: (a) Nissl stained section compared to an orthogonal coronal projection from the AIBS
histology-based template. The nissl stained section was cut at an non-orthogonal angle
seen e.g. by the hippocampus (white arrow). (b) Interpolated atlas projection matching
the cutting angle of the Nissl stained section.
4.3 Spectral unmixing
Spectral unmixing algorithms can be divided into two groups; one requires that the sample is sequen-
tially scanned through the frequency range [DBT+01], and the other requires only a few spectrums to
be are recorded [MHN+10]. The second type is referred to as blind unmixing. Blind unmixing saves
time in acquisition, however it does rely on more assumptions as less data is available. In this work a
blind unmixing algorithm was developed as it was not feasible to obtain the full frequency spectrum
for every brain sample. Algorithm 1 describes the blind unmixing algorithm developed and used in
this phd project to reduce auto-fluorescence in images of fluorescently labelled peptides.
Algorithm 1 compute unmix channel
1. Load auto-fluorescence channel (auto)
2. Load specific channel (spec)
3. Compute histogram of non-zero voxels from auto with 40 bins
4. Pre-allocate result volume (unmix)
5. For each histogram bin
6. tempInd = indicies of voxels within histogram bin
7. tempCoeff = median(auto(tempInd)) / median(spec(tempInd))
8. Unmix(tempInd) = spec(tempInd) - (auto(tempInd) ./ tempCoeff)
9. End
10. Save unmix channel (unmix)
In line 1 and 2 the acquired LSFM data containing an auto-fluorescence channel and a specific channel is
loaded into memory. In line 3 a histogram is computed for the non-zero values of the auto-fluorescence
channel. For each of the histogram bins the voxels contained in each bin is selected (line 6) and the
median of those voxels is computed for the auto channel and specific channel respectively. A coefficient
equal to the ratio between the two median values is computed by division (line 7). The unmix version
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of the voxels is computed by subtracting the estimated auto-fluorescence from the acquired specific
channel (line 8).
In essence the idea of the algorithm is that the recorded specific channel contains signal from the
labelled peptide (wanted signal) as well as auto-fluorescence from the tissue (un-wanted signal). By
estimating the auto-fluorescence contribution in the specific channel and subtracting it from the image
only the contribution from the labelled peptide is left (Fig 4.5). The auto-fluorescence in the specific
channel is estimated as a linear function in each histogram bin. For the algorithm to work it is assumed
that the number of voxels with signal from labelled peptides is low (minimal influence on median value
computed in each bin), and that the auto-fluorescence of the tissue is more intense at lower wavelengths.
Figure 4.5: Left: Sagital projection of acquired auto-fluorescence channel. Middle: Corresponding
sagital projection of the specific channel. Right: Corresponding sagital projection of
computed unmix channel.
4.4 Cell segmentation
In the experiments involving whole brain staining a different approach was used to enhance the specific
signals used as input for the subsequent statistical analysis. Instead of using the acquired specific
channel (or the unmix version) heat maps were computed to provide a compact representation of
the acquired whole brain stained signals. The heat maps were based on cell segmentation of positive
stained cells. Cell segmentation was performed based on blob filters in combination with morphological
operations.
By viewing an image as a function of two variables with the voxel intensity being the function value a
blob filter can be constructed based on the eigenvalues of the local hessians at each image point. The
Hessian matrix or hessian is a square matrix of second-order partial derivatives, and thus describes the
local curvature. The top-hat filter is used to enhance bright objects of interest in a dark background.
Top-hat filtering computes the morphological opening of the image based on a structuring element,
e.g. a disk, and then subtracts the result from the original image. Essentially, the filters suppress large
regions while keeping the small ones as specified by the size of the structuring element.
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Algorithm 2 describes the cell segmentation algorithm used prior to constructing the heat maps. The
cell segmentation algorithm is applied to each acquired 2D image of the LSFM scan sequence one by
one. In line 3, two eigenvalues of the hessian matrix are computed for each voxel in the image of
the specific channel. In line 4, a feature is constructed by addition of the eigenvalues to enhance the
contrast of blob shaped objects in the image. In line 5, top-hat filtering is used to remove uneven
background illumination from the image. For six iterations the sequence of blob filtering and top-hat
filtering is repeated to separate larger clusters of cells into individual cells (line 6-10). In line 11, a
binary image of the voxels containing positive stained cells is constructed by thresholding. An example
showing the cell segmentation algorithm is seen in Figure 4.6. After cell segmentation a heat map was
created by summing uniform intensity discs with diameter of 20 µm placed on each voxel representing
a cell. These heat maps were later used for visualization and quantification.
Algorithm 2 cell segmentation
1. Load auto-fluorescence channel (auto)
2. Load specific channel (spec)
3. [lambda1, lambda2] = blobFilter(spec)
4. feature = lambda1 + lambda2
5. ICell = imtophat(imcomplement(feature))
6. For i=1:6
7. [lambda1, lambda2] = blobFilter(ICell)
8. tempFeature = lambda1 + lambda2
9. ICell = imtophat(imcomplement(tempFeature))
10. End
11. ICellFinal = ICell > threshold
Figure 4.6: (a) Raw image of whole brain stained sample acquired with LSFM. (b) Higher magnifi-
cation of the red square in (a). The bright dots are positive stained cells. (c) Result of
applying Algorithm 2 to obtain a binary representation of the cells.
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4.5 Statistical analysis
In this PhD project the most used statistical analysis was comparison of specific signals within a num-
ber of brain regions between different study groups. The specific signals may be unmixed fluorescent
signal (labelled peptides), or the signals of generated heat maps (whole brain staining). The aim is to
compare the total signal in a brain region between different study groups e.g. animals treated with
a pharmaceutical compound compared to vehicle. If one think that the mean total signal in a brain
region between treatment and vehicle are equal this may be stated as:
H0 : µ1 = µ2
H1 : µ1 6= µ2
where µ1 is the mean total signal in the brain region of treated animals and µ2 is the mean total signal
in the brain region of vehicle injected animals. H0 is called the null hypothesis and H1 is called the
alternative hypothesis. In this example the alternative hypothesis is two-sided because it would be true
if either mean value is larger than the other. The hypothesis is tested by computing an appropriate
test statistic to either reject or fail to reject the null hypothesis. When testing the hypothesis, two
types of errors may be committed:
α = P (type I error) = P (reject H0 | H0 is true)
β = P (type II error) = P (fail to reject H0 | H0 is false)
where α is the probability of rejecting the null hypothesis when it is true, and β is the probability
of not rejecting the null hypothesis when it is false. When testing the hypothesis, α, also called the
significance level, is normally specified. In this PhD project the two-sample t-test [Mon17] has been
used for hypothesis testing. With this test it was assumed that the samples originated from two inde-
pendent normal distributions with equal variance.
In the studies presented in this PhD project a digital brain atlas was used in combination with image
registration to automatically extract the total specific signal in a range of brain regions, leading to
multiple t-tests. A way to control the error rate under multiple testing is the concept of false discovery
rate (FDR) [BH95]. When multiple tests are performed the goal is to determine a subset of brain
regions where the differences seem substantial enough to pursue for further testing. If this subset
of brain regions is referred to as discoveries, FDR allows the researcher to tolerate a certain number
of tests to be incorrectly discovered. The FDR-controlling procedure introduced by Benjamin and
Hochberg [BH95] can be described as follows: Consider testing N hypotheses, H1, H2, ..., HN based
on their corresponding p-values, p1, p2, ..., pN . Allow a fraction q of discoveries to be false. Sort the
p-values in ascending order, p(1) ≤ p(2) ≤ ... ≤ p(N) and denote H(i) the hypothesis corresponding to
p(i). Let k be the largest i for which p(i) ≤ i/N · q. Then reject all H(i), i = 1, 2, ..., k. In this PhD
work the FDR procedure was used to control for multiple testing.
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4.6 Active appearance models
Activate appearance models (AAMs) were in Paper E investigated as an alternative segmentation
strategy for LSFM images. AAMs can be used to segment shapes in images [CET01]. The idea is to
construct models of the shapes of interest based on manual annotated training images, and to use these
models to segment the shapes in novel images. The motivation is to achieve robust segmentation by
using the trained AAMs to constrain segmentation solutions to be valid examples of the class of images
and shapes being modeled. The AAM is constructed to model the shape variation and texture variation
[CET01]. By texture is meant the pattern of intensities across an image patch. To construct the model
a set of images with corresponding landmarks is required. In this PhD work a model was constructed
of five brain region shapes (VL, DG1, DG2, ZI, and SPVC). Four to six corresponding landmarks were
manually annotated on similar coronal sections extracted from acquired LSFM data (Fig. 4.7a). Each
shape was equidistantly up-sampled to consists of 40 landmarks per shape, and normalized by the
generalized procrustes analysis (GPA) [DM98]. A shape variability model was constructed based on
the eigenvectors of the Nd x Nd shape covariance matrix, where d is the number of image dimensions,
and N is the number of landmarks used to represent each shape (Fig. 4.7b). The texture variability
model was similarly constructed based on eigenvectors of the Kd x Kd texture covariance matrix, with
K equal to the number of intensities sampled from each training example. To make the model robust
despite of inhomogeneous illumination seen with LSFM acquisition of large tissue samples the texture
was modeled using the regularized Normalized Gradient Field (rNGF) [HM06] instead of the original
pixel intensities. The final AAM was constructed by concatenating the parameters of the individual
shape and texture models and performing an additional eigen decomposition. Figure 4.7c shows an
example of using the constructed model to segment the shapes from a novel image not previously seen
by the model.
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Figure 4.7: (a) Left: Sagtial atlas plate from the AIBS reference atlas. Right: Sagtial projection of
LSFM data with labelled brain regions and manually positioned landmarks. (b) Left:
Landmarks representing the variation in shape of the five modeled brain regions. Middle:
Landmarks aligned by GPA. Right: Constructed shape model. (c) Segmentation using
the model. From an initial start guess the model converges toward a solution over a
number of iterations.
Part II
Applications

Chapter 5
Data integration
This chapter presents the result obtained by combining the different aspects of the methodology pre-
sented in Part I of the thesis to construct an integrated brain atlas enabling automated quantification
of brain receptor expression, brain distribution of labelled peptides, brain activation and to some de-
gree brain connectivity. A developed atlas is used to automate analysis of data from the modalities
presented in Section 3.1 and 3.2 utilizing the image analysis tools presented in chapter 4 in order
to help answer biology questions related to the peptides presented in Section 2.1.1 and 2.1.2. The
integrated brain atlas was directly used to obtain the results in Paper A and D, while a less mature
implementation of the atlas was used to obtain the results in Paper B and C.
5.1 Integrated brain atlas
The CCFv3 from AIBS (Section 4.1.1) was used as basis for constructing an integrated brain atlas to
enable quantification and comparison of data regarding brain access, receptor location, brain activity,
and brain connectivity. The atlas implementation combines user data from LSFM and histology sec-
tions, as well as connectivity maps downloaded from the AIBS data portal (Fig. 5.1). Brain access and
brain distribution was visualized by LSFM imaging of in vivo-dosed fluorescently labelled peptides.
Brain receptor location was mapped using IHC (in 2D and 3D). Whole brain IHC was used to visualize
brain activation. Brain connectivity was added to the atlas based on connectivity maps downloaded
from the AIBS data portal. For exploration purposes, all mapped data were imported into a commer-
cially available software program allowing visualization of 3D maximum intensity projections as well
as sagittal, horizontal, and coronal 2D projection images. Automatic extraction of statistical measures
in brain regions of interest was performed using the annotation model of the CCFv3 from AIBS.
32 Data integration
The aim of the atlas is to integrate data sets from different sources. This was enabled by providing
data sets with two main components: 1) anatomy information and 2) specific signal information. The
anatomy information was used to spatially align the data using image registration as described in
Section 4.2, while the specific information helped answer biological questions. Furthermore, collecting
all experiment data into a common reference atlas allows the user to gather an anatomical database of
information which can be directly compared to parallel and future studies. The following subsections
describe strengths and weaknesses of the current atlas implementation.
Figure 5.1: (1) Anatomy from auto-fluorescence. (2) Receptor mapping from whole brain IHC, here
GLP-1R. (3) Brain access seen by fluorescently labelled antibody against the fenestrated
capillaries. (4) Brain distribution of fluorescently labelled peptides, here liraglutideVT750.
The 2D histology section is included to indicate that such sections can be aligned to
3D LSFM data. (5) Brain activation from whole brain staining, here c-Fos response to
liraglutide treatment. (6) Brain connectivity visualized by connectivity maps downloaded
from the AIBS data portal. All data set were mapped to a common reference space to
create the integrated brain atlas.
5.1.1 Fluorescently labelled peptides
The use of fluorescently labelled compounds allows the researcher to track the administered compounds
directly using LSFM. Such experiments provide information about how the peptides distribute which
is important information during development of a pharmaceutical compound. However, one challenge
with fluorescently labelled compounds is that the attached fluorephore may change the chemical char-
acteristics of the compound such that e.g. the pharmacokinetic profile is different between the labelled
and unlabelled version of the compound. The fluorephore itself may potentially even change the distri-
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bution, e.g. allow or restrict access compared to the unlabelled molecule. With fluorescently labelled
liraglutide used in Paper A a good correspondance between fluorescently labelled and radioactive (3H)
labelled liraglutide in terms of brain access and distribution has previously been showed (unpublished
data). Fluorescently labelled liraglutide also has comparable biological effects regarding body weight
loss and appetite regulation in mice (data not shown).
5.1.2 Whole brain IHC
Whole brain IHC was utilized in this thesis to visualize receptor localization and brain activation
markers. The method may however be used to study any antigen with an available antibody. One of
the technical challenges with larger tissue samples such as a whole mouse brain is tissue penetration
by the antibody. Ideally the availability of the antibody should be uniform through the tissue sample,
however in many cases more antibody will be available near the edges of the sample and less antibody
available in the deeper parts of the sample. This leads to a bias in the image intensities when the tissue
samples are imaged with LSFM. In this thesis quantification of whole brain IHC stained samples was
performed by first performing a segmentation of positively stained cells and then constructing heat
maps from the resulting binary representation. In this way the effects of the non-uniform antibody
penetration is minimized in the quantification. On the other hand, the difference in intensity of the
positively stained cells will in some cases also provide relevant biological information which is currently
not reflected in the performed quantification.
5.1.3 Connectivity maps
The ability to automatically search the publicly available connectivity maps from AIBS based on
acquired LSFM data provides an opportunity to gain a more comprehensive understanding of the
acquired data. In this thesis the connectivity maps were used to investigate secondary brain activation
seen following liraglutide treatment. The challenge is that although more than 2000 connectivity
maps are available this is still only a limited subset of the full brain connectome. Updates with more
connectivity maps are regularly made available on the AIBS website and by adding these the tool
will continue to gain value. A similar resource available from the AIBS website is gene expression
data of approximately 20.000 genes in the mouse brain based on ISH. Going forward these could also
be downloaded and automatically be compared to LSFM data in a similar way as the connectivity
maps. It should be noted that these types of analyses are hypotheses generating tools; hence follow up
experiments should be performed to validate findings.
5.1.4 2D sections
The ability to directly compare 3D LSFM data with 2D histology data allows the researcher to gain
a broader understanding of the data. A case where this method is useful is regarding data from ISH.
Whole brain ISH is not commonly used so to directly compare LSFM data with ISH data a tool like
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the one developed in this thesis is needed. As described in Section 4.2.2 the cutting of sections are
often not orthogonal so interpolated atlas plates are needed for correct registration. In the current
implementation this interpolation is performed by the user which lead to operator bias. To avoid this
bias automated construction of an interpolated atlas section is needed, or alternatively a direct method
for registration between a 2D section and the 3D atlas.
5.1.5 Registration quality
The usefulness of the developed brain atlas largely depends on the registration quality. All brain
samples are ex vivo samples which lead to more difficult registrations compared to e.g. in vivo data
where the brain still sits in the skull. The process of removing the brain often leads to mechanical
damage to the tissue seen as small or large tissue cracks in the acquired data. Furthermore, as
described in Section 4.2.1 the applied tissue preparation protocol for LSFM causes non-uniform tissue
deformation with different parts of the brain shrinking more than others. These challenges made it
difficult to select proper regularization parameters for the registrations. To mitigate these problems a
registration model was introduced where larger individual parts of the brain was registered alone and
combined to create the final result. Especially the computation of a different affine deformation for
each of the larger brain structures improved the segmentation quality. The registration quality was
tested as part of the work in Paper A. Based on manually positioned landmarks the average error was
around 5 voxels corresponding to 100 µm. Going forward, new tissue preparation protocols such as
e.g. [PCQ+16] may led to less tissue deformation and improved alignment to the digital atlas.
Chapter 6
GLP-1
This chapter presents how the registration and segmentation methods presented in Chapter 4 were
applied to investigate effects of GLP-1RAs related to appetite regulation. The GLP-1R brain expression
was mapped, as well as the brain distribution following peripheral administration of the GLP-1RAs
liraglutide and exendin-4. Brain activation in response to liraglutide treatment was also investigated,
and connectivity maps from AIBS were used to infer information on observed secondary activation.
The results presented here are summaries of the results obtained in Papers A, B, and C.
6.1 GLP-1R mapping
In paper B the aim was to show the detailed distribution of GLP-1R immunoreactivity in combination
with mapping of GLP-1R mRNA by non-radioactive ISH. This was done in part to compare the results
obtained using the different staining approaches, and also to construct a set of anatomical reference
plates to summarize the GLP-1R distribution through the mouse brain.
Image segmentation of the acquired IHC and ISH slide scanner images were performed using a multino-
mial regression classifier based on r,g,b image features. Prior to segmentation each IHC/ISH image pair
was registered to a digital atlas plate obtained from the Allen mouse brain reference model (Fig 6.1c).
In some regions mRNA and protein expression co-exists (Fig. 6.1d-e), but in other regions e.g. only
protein expression were seen (Fig. 6.1f-g). The strength of using a specific antibody was emphasized
by the ability to detect GLP-1R protein in regions devoid of mRNA and in neuronal projections where
expression was not observed previously using a transgenic reporter system [CRH+15]. The GLP-1R
was abundantly expressed in numerous brain regions including the septal nucleus, the hypothalamus
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and the brain stem. In total 22 atlas plates were constructed showing the localization of the GLP-1R
through the mouse brain (Paper B, Fig 2).
Even though 22 sections provide comprehensive information on the GLP-1R distribution the approach
of using 2D sections has limitations. As mentioned GLP-1R expression was observed on neural projec-
tions, but it is difficult to track axons through a set of sections. Going forward, the use of whole brain
IHC staining will be a valuable tool to track these projections and gain and even better understanding
of the GLP-1R distribution.
Figure 6.1: (a) Example of ISH image. (b) Example of IHC image. (c) Atlas plate obtained by
automatic drawing of markers representing segmented signal following a 2D registration
of the images in (a-b) to a digital atlas plate from AIBS. Blue circles correspond to the
segmentation of the IHC image, and the red squares correspond to the segmentation of
the ISH image. Brain regions with either positive IHC or ISH signal is highlighted with
a fill color. (d-g) Zoom images shown for black boxes in (a-b).
6.1.1 Brain distribution of GLP-1RAs
As the GLP-1R was shown to be widely distributed throughout the mouse brain and since GLP-1 is
also a neurotransmitter produced in hindbrain neurons [TC15], it is of interest to examine which GLP-
1Rs are accessible to peripheral injected GLP-1RAs. In paper A the brain distribution of peripheral
administered liraglutideVT750 was mapped to evaluate which brain regions could potentially be directly
activated by the compound. In paper C the distribution of another GLP-1RA exendin-4 was quantified.
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6.1.2 Liraglutide distributes to hypothalamus, hindbrain and cerebral nu-
clei
Fluorescently labelled liraglutide was injected in vivo and mouse brains were removed after six hours
and compared to brains from vehicle injected animals. Using the nomenclature of the AIBS mouse
brain atlas, liraglutideVT750 was significantly detected in CVOs such as AP and OV, as well as in regions
shielded by the BBB such as ARH and paraventricular hypothalamic nucleus (PVH). LiraglutideVT750
was also observed in chpl, exemplified by the plexus located in V4 and VL (Fig. 6.2a). An average
liraglutideVT750 distribution signal was computed and imported into the integrated brain atlas for
visualization (Fig. 6.2b). The signal in the chpl was not thought relevant as no GLP-1R was present
on these cells. By comparing to the broad distribution of GLP-1R this study showed that liraglutide
targets a subset of receptors localized in the hypotalamus, hindbrain and cerebral nuclei.
Fluorescently labelled exendin-4 was likewise injected in vivo and the brains were removed after two
hours and compared to vehicle injected brains. Using the nomenclature of the AIBS mouse brain
atlas, exendin-4VT750 was significantly detected in AP, Nucleus of the solitary tract (NTS), ME, ARH,
Periventricular hypothalamic nucleus, posterior part (PVp), OV, Septofimbrial nucleus (SF), and Lat-
eral septal nucleus, caudal part (LSc). Overall, the distribution of exendin-4VT750 was similar to that
of liraglutideVT750. However, differences was observed mainly in the LSc were exendin-4VT750 signal
was strong, but no liraglutideVT750 signal was seen. Conversely, liraglutideVT750 signal was observed in
the PVH, were almost no exendin-4VT750 signal was observed. This is interesting as both compounds
are GLP-1RAs, but still show a different brain distribution.
As the GLP-1RAs have different pharmacokinetic profiles and as the distribution studies only consists
of a single time point each one could speculate that the observed difference in distribution is merely
due to the difference in plasma concentrations of the compounds at those time points. However, this is
not the case as multiple studies with different time points have been performed during the PhD project
(data not shown). The liraglutideVT750 distribution has e.g. been evaluated after 10 minutes, 6 hours,
24 hours, and 48 hours without showing a signal in LSc. A dose dependency study of liraglutideVT750
has also been conducted which led to the conclusion that the distribution does not change as function
of dose concentration, i.e. a higher concentrations will not lead to signal in new brain regions (data
not shown). The distribution differences between the GLP1-RA compounds are thus probably due to
their different chemical structures.
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Figure 6.2: (a) Bar graph showing the mean fold change and standard deviation (SD) of the total
fluorescence signal in selected brain regions comparing liraglutideVT750 and vehicle (n=5).
An asterisk marks significant difference between treatments when analyzed in individual
brain regions using a false discovery rate value of 5% to correct for multiple comparisons.
Note the split y-axis when interpreting results and SD. See Supplementary Table 1 for full
brain region names. (b) Maximum intensity projection of the average liraglutideVT750
signal computed from the individual brains in the study group (n=5).
6.1.3 The liraglutide distribution is GLP-1R dependent
In Paper A the ISH platform RNAscope [WFS+12], [AZM+16] was used to map the glp-1r mRNA
location in a number of coronal slides throughout the C57BL/6J mouse brain. A heat map was
computed from the ISH section to represent the glp-1r positive cells, and this heat map was aligned
to the integrated brain atlas, which enabled direct visual comparison with the average liraglutideVT750
distribution. An example of a mapped glp-1r ISH heat map compared to the corresponding anatomical
location in the average liraglutideVT750 distribution signal is seen in Paper A, Fig. 6. Overlap was
seen in Supraoptic nucleus (SO) and SFO, while a liraglutideVT750 signal was also observed in the
chpl located in VL where no receptor signal was present. Overall, all regions with liraglutideVT750
distribution also showed glp-1r mRNA except ME and chpl in the ventricular system. We know
however from Paper B that GLP-1R is present in ME so this region may be added to the list of regions
with a possible direct activation from liraglutide. The GLP-1R dependence was further validated as
liraglutideVT750 signal was lost in glp-1r-/- mice except for signal in chpl.
6.2 Brain activation in response to liraglutide treatment
Knowing the GLP-1R brain distribution and the subset of these GLP-1Rs targeted by liraglutideVT750,
the next step in Paper A was to investigate possible change in brain activation following liraglutide
treatment. The brain activation pattern was compared to the average distribution of liraglutideVT750
and connectivity maps from AIBS to delineate direct versus secondary activation.
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6.2.1 Liraglutide treatments leads to activation in brain regions related to
food intake
C57BL/6J mice were dosed subcutaneously with liraglutide, and the c-Fos response was compared to
vehicle dosed controls four hours after treatment. The most prominent c-Fos increase following li-
raglutide injection was seen in Bed nuclei of the stria terminalis (BST), Paraventricular nucleus of the
thalamus (PVT), Central amygdala nucleus (CEA), Parabrachial nucleus (PB), and NTS (Fig. 6.3a).
Heat maps were constructed for each individual brain sample based on the number of c-Fos positive
cells and aligned to the integrated brain atlas (Fig. 6.3b). The heat maps were used to quantify the
differences between liraglutide and vehicle dosed animals in select brain regions (Fig. 6.3c). Brain
activation in PB, CEA, and BST has previously been described to be related to lowering of food intake
through a pathway involved in meal termination [CSZP13], [CHAA14].
In the interpretation of the study results it is again important to note that the activation is only
evaluated at a single time point after treatment. A similar brain activation profile was however seen
after chronic dosing of liraglutide (data not shown). Also, c-Fos is an activation marker, but direct
effects of liraglutide may also cause inhibition, e.g. lead to decreased brain activity in certain regions.
In this study we were not able to identify brain regions where liraglutide treated animals had decreased
brain activation compared to vehicle treated animals. An interesting study would be to perform the
same experiment in hungry mice to explore if liraglutide perhaps could lower activity in brain regions
which promote food seeking an increased appetite. A final consideration is that brain activity may
occur without detection by c-Fos. Thus one can not conclude that no activation occurs in e.g. cerebral
nuclei just because no c-Fos increase was seen. It will be interesting to investigate more activation
markers going forward.
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Figure 6.3: (a) Example images of c-Fos response in liraglutide vs vehicle dosed mice. Bregma coordi-
nates denote the anatomical location. (b) c-Fos heat map computed from one liraglutide
injected mouse. (c) Bar graph showing the mean fold change and SD of total c-Fos heat
map signal in selected brain regions comparing liraglutide and vehicle dosed animals.
An asterisk marks significant difference between treatments when analyzed in individual
brain regions using a false discovery rate value of 20% to correct for multiple comparisons.
6.2.2 Brain activation appears to be a combination of direct and secondary
activation
To investigate whether the observed c-Fos response could be direct effects of liraglutide interaction with
GLP-1R a visual comparison of the liraglutide specific c-Fos increase with the liraglutideVT750 distri-
bution from Fig. 6.2b was performed. The c-Fos increase was computed by subtraction of the average
c-Fos signal in the vehicle group from the average signal in the liraglutide treated group (Fig. 6.4a).
Some overlap was seen between the liraglutideVT750 distribution and the c-Fos increase (Fig. 6.4b),
mainly in the hindbrain indicating possible direct activation from liraglutide in this area. However, the
majority of c-Fos increase was seen in regions not overlapping with the liraglutideVT750 distribution,
indicating secondary activation.
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To investigate the observed secondary brain activation, the brain connectivity maps from AIBS were
automatically ranked in regards to the similarity with the c-Fos increase. Projections from the lateral
PB were seen in four of the ten most overlapping connectivity maps compared to the liraglutide specific
c-Fos increase. As liraglutideVT750 showed no significant access in the PB, this suggests a role of the PB
as a relay station of input from other targeted brain regions. Glutamatergic (slc17a6-IRES-Cre) projec-
tions from the lateral PB (4th most overlapping connectivity map) were imported into the integrated
brain atlas to visualize how these neurons could be part of the secondary c-Fos response following
liraglutide treatment (Fig 6.4c). This parabrachial pathway has in recent literature been described as
a general circuit causing anorexia [CSZP13], [CHAA14], [CBSP16] and from the results also appears
to be involved in the brain activation from liraglutide treatment. In connection with this literature it
is described how the PB is activated from the AP/NTS which also fits well with observations about
possible direct activation from liraglutide in these regions (Fig. 6.4b).
However, it must be noted that these analyses of overlaying the brain activity signal with the liraglutideVT750
distribution signals and connectivity maps from AIBS provides hypotheses and not actual confirma-
tion. To further test the generated hypothesis of direct activation in the hindbrain, one could e.g.
co-stain for c-Fos and GLP-1R in sections including AP/NTS of liraglutide treated animals. To test
the hypothesis of secondary activation relayed by the PB one could e.g. co-stain for c-Fos and cgrp
which is a marker of a subpopulation of neurons in the PB described to be involved in meal termination
[CBSP16].
Figure 6.4: (a) Maximum intensity projection of the average c-Fos increase following liraglutide treat-
ment (blue). Signals are overlaid onto the CCFv3 template from AIBS. (b) Maximum
intensity projection of the average liraglutideVT750 distribution (purple) overlaid with
the average c-Fos increase following liraglutide treatment (blue). (c) Maximum intensity
projection of downloaded glutamatergic projections from PB (yellow) overlaid with the
average c-Fos increase following liraglutide treatment (blue).
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Chapter 7
Leptin
This chapter presents how the registration and segmentation methods presented in Chapter 4 were
applied to investigate brain activation in response to leptin treatment. LepRb was mapped to select a
subset of brain regions for further analysis of the brain response to exogenous leptin. Brain activation
in response to leptin treatment was mapped at different time points after treatment and in different
animal models. The results presented here are summaries of the results obtained in Paper D.
7.1 Mapping of LepRb
In paper D the aim of the receptor mapping was to detect brain regions where exogenous leptin may
have a direct effect through LepRb. A genetic model previously utilized by Patterson et al. [PLJM11]
was here also used to map the receptor localization. Three LepRbEGFP mouse brains were scanned
using LSFM to image the whole brain in 3D. As previously described the LepRb distribution was
broad and scattered throughout the mouse brain. High concentrations of receptor were seen in corti-
cal regions, hypothalamic regions, midbrain regions and hindbrain regions. Cortical regions included
Dorsal auditory area (AUDd), Supplemental somatosensory area (SSs), and Ectorhinal area (ECT).
Hypothalamic regions included ARH, DMH, and Lateral hypothalamic area (LHA). Midbrain regions
included dorsal nucleus raphe (DR), Periaqueductal gray (PAG), and Ventral tegmental area (VTA).
Hindbrain regions included PB, NTS, and Dorsal motor nucleus of the vagus nerve (DMX). Based
on receptor expression in these brain regions leptin potentially has the ability to directly affect both
homeostatic feeding, meal generated signals, and reward driven feeding [MMLL09].
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The LepRbEGFP mouse model expresses enhanced green fluorescent protein (EGFP) under a LepRb
promoter which means that fluorescence signal is observed in cells that express mRNA coding for
LepRb. These signals are restricted to the cell soma which means that LepRb potentially could be
expressed on axonal projections (as were seen with GLP-1R) or in synaptic cliffs without detection
in this setup. A specific antibody against LepRb is needed to investigate this concern. However, no
apparent pStat3 signal was observed in the later experiments in regions not showing LepRb expression
in the LepRbEGFP model.
7.2 pStat3 activation in response to leptin treatment
In paper D the aim was to investigate why peripheral leptin treatment is not an effective obesity
treatment despite that leptin promotes weight loss in non-obese individuals [HBBW+97]. In this PhD
work, two main experiments were performed to: 1) evaluate the time course of the brain activation
following a peripheral leptin injection, and 2) evaluate the difference in brain activation between lean
and obese mice. Brain activation was evaluated based on pStat3 as this is a commonly used marker
for direct activation of the LepRb [MFB04].
Following peripheral administration of leptin, animals were euthanized after 10 min., 30 min, 60 min,
120 min, and 240 min. The brains were extracted and imaged using LSFM after whole brain IHC
staining for pStat3 (Fig. 7.1a). Heat maps representing the number of cells positive for pStat3 were
created and quantified using the integrated brain atlas. It was observed that the pStat3 response
peaked at different time points in different brain regions, although most activation peaked between 60
min. and 120 min. as e.g. seen in Ventromedial hypothalamic nucleus (VMH) (Fig. 7.1b).
Next, the potential differences in brain activation to exogenous leptin between lean mice and obese
mice were investigated. Diet induced obese (DIO) mice were included as these mice mimic the human
obesity epidemic partly driven by easy access to highly palatable foods which leads to leptin tolerance
or resistance [BM09]. Brain activation was evaluated 60 minutes after subcutaneous leptin injection.
The lean mice showed strong brain activation after leptin injection and low baseline activation with ve-
hicle injection. The activation was most prominent in the hypothalamic regions. The DIO mice showed
an attenuated response to leptin and higher baseline activation compared to lean mice. Quantification
of the pStat3 response in eight hypothalamic regions showed a large dynamic in the lean model with
fold changes ranging from 6.35 (ARH) to 285.06 (LHA) between leptin and vehicle treated animals
(Fig. 7.2a). This increase in pStat3 activation was not seen in the DIO model where the largest fold
change was modest 2.66 (PH) (Fig. 7.2b). The study showed that exogenous leptin provides little
additional information to the brain compared to baseline conditions in the DIO mouse and this could
be a hint to why leptin is not an effective obesity treatment.
The analysis was focused on the hypothalamic regions as this was the region with the strongest pStat3
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signals. However, the same picture with a lowered dynamic in DIO model was also observed in the
hindbrain, primarily seen in DMX and NTS. Little to no pStat3 signal was observed in areas of the
limbic system such as in VTA or Nucleus accumbens (ACB) in either of the mouse models. Going
forward, it could be interesting to explore secondary brain activation following leptin treatment in lean
and DIO mice as this might provide further knowledge about leptin resistance.
Figure 7.1: a) Examples of whole brain pStat3 stained brains from animals euthanized at different
time points after peripheral leptin injection. The strongest activation signal was seen in
the hypothalamus (white arrow). (b) Coronal sections of average heat maps generated
for each time point. Heat maps are overlaid onto the CCFv3 template from AIBS. It is
seen that the activation in general is strongest between 60 min. and 120 min.
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Figure 7.2: (a) Ratio of pStat3 activation between leptin and vehicle treated lean mice. All brain re-
gions showed significant activation following leptin treatment using multiple comparisons
with FDR correction of 5%. Note the log scale when interpreting standard deviations.
(b) Ratio of pStat3 activation between leptin and vehicle treated DIO mice. No brain
regions showed a significant activation increase from leptin treatment.
Chapter 8
User interface
This chapter describes how the integrated brain atlas and the most used algorithms were implemented
at Novo Nordisk A/S to enable other researchers to use the developed analysis tools. This was an
important milestone as this is an industrial PhD project. Thus researchers at the company should be
able to continue using the automated quantification of LSFM data after the PhD projected has ended.
The developed algorithms were linked to Imaris which is a commercial software for 3D image viewing
used at Novo Nordisk. The developed algorithms are made available through the image analysis menu
located in the software. The integrated brain atlas is the backbone of the algorithms and all data sets
aligned to the atlas are saved as open source nifti files for storage. The nifti files also allow the user
to import specific brain signals from different experiments into the same Imaris file for explorative
work and visualization. User input to the algorithms, as well as output such as extracted variables for
statistical analysis, are exported to Microsoft excel files.
8.1 Developed scripts
Two main analysis pipelines were developed during the PhD project. The first pipeline enables auto-
mated quantification of LSFM data to analyze in vivo injected fluorescently labelled peptides in the
whole brain. Data is acquired in 10.32 um isotropic resolution with one channel containing anatomical
information from auto-fluorescence and another channel containing specific information from the la-
belled peptide. To analyze the data the user fills out an excel template with information on the location
of the acquired image files, which study groups the individual brains belong to, and the desired location
for result files to be saved. The algorithm will then construct an unmix version (Section 4.3) of the spe-
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cific channel together with a preprocessed version of the auto-fluorescence channel. The preprocessed
auto-florescence channel is registered to the LSFM template of the integrated brain atlas and the unmix
channel is transformed to the atlas space using the computed parameters. Once image data of all brain
samples from the experiment are aligned to the atlas space, average signals representing the different
study groups of the experiment are constructed by averaging the aligned unmix channels. These av-
erage signals may later be imported into the same Imaris file to visually compare the experiment groups.
The second pipeline enables automated quantification of LSFM data from whole brain IHC stained
brain samples. Data is acquired in 4.06 um isotropic resolution with one channel containing anatom-
ical information from auto-fluorescence and another channel containing specific information from the
stained cells. The analysis is the same as for the labelled peptides, however instead of a representation
of the specific signal by an unmix channel, in this case the specific signal is represented by a heat map
constructed based on the number of positive stained cells (Section 4.4). Once all heat maps repre-
senting the samples from the experiment are aligned to the atlas space, average signals representing
the different study groups of the experiment are constructed by averaging the constructed heat maps.
These average signals can again be imported into an Imaris file to ease visual comparison of the ex-
periment groups.
Table 8.1 provides an overview of the implemented scripts. As all aligned brain samples can be imported
into any Imaris file it is easy to compare information from different studies and study types. Figure 8.1
shows an example of aligned nifti files from different experiment loaded into the same Imaris file. Once
imported to Imaris, 2D projections, maximum intensity projections, and movies can be constructed.
Plugin Study type Purpose Output
CCFv3 Labelled peptide Visualize and quan-
tify labelled peptides
Individual unmix channels
(nifti). Average brain
(nifti). ROI statistics (ex-
cel).
iDISCO Whole brain staining Visualize and quan-
tify whole brain
stained samples
Individual heat maps
(nifti). Average brain
(nifti). ROI statistics
(excel).
Import
nifti
Labelled peptides +
whole brain staining
Import brain signals
to the integrated
brain atlas for easy
visual comparison
Table 8.1: Developed scripts made accessible through the commercial Imaris software.
8.2 Number of analyzed brain samples 49
Figure 8.1: Left: Coronal projection of different data sets all aligned and imported into the same
Imaris file for easy visual comparisons. The signals are overlaid onto the CCFv3 template
from AIBS. Middle: Same data set now visualized as a 3D maximum intensity projection.
Right: Screenshot from the Imaris user interface showing the different channels imported
into the Imaris file. The user can tick on and off the different channels as well as adjusting
color maps.
8.2 Number of analyzed brain samples
To highlight the usage of the developed scripts a count was performed regarding the number of indi-
vidual brain samples analyzed each month during the last year of the PhD project (Fig. 8.2). The
brain samples analyzed came from a mix of studies related to this PhD project as well as different
research projects at Novo Nordisk. The total number of quantified brains within the last year was 466.
The largest number of brains quantified in a single month was 80 which demonstrate the need for an
automated analysis approach.
Figure 8.2: Number of brains analyzed within the last year of the phd project using the developed
atlas approach for automated quantification.
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Chapter 9
Active appearance segmentation
This chapter describes how the AAMs presented in Section 4.6 was used to segment selected brain
regions in 2D sagital projection images from LSFM data. An AAM constructed based on rNGF was
evaluated in terms of robustness to common LSFM artefacts. The results presented here are summaries
of the results obtained in Paper E.
9.1 Segmentation quality
The aim of paper E was to evaluate the influence of common LSFM artifacts on the segmentation
quality of a novel approach to constructing an AAM with the texture model based on rNGF instead of
the classical SSD. LSFM systems are prone to different artifacts such as inhomogeneous illumination
and possible blurry images. The inhomogeneous illumination may arise from suboptimal clearing of
tissue samples, or from the imperfect characteristics of the generated light sheet especially seen with
larger tissue samples. Blurry images may arise when the operator does not adjust the focus of the
microscope correctly.
The first experiment investigated the effect of manipulating the images by applying a controlled arti-
ficial bias field to mimic slowly varying spatial intensity inhomogeneities. The Dice score [Dic45] was
used to evaluate the quality of the segmentation. The overall Dice score of the model as function of the
bias field strength was observed to degrade faster with the model based on the SSD similarity measure
compared to the model based on rNGF.
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The second experiment investigated the AAM model performance using a test set of images with com-
mon LSFM imperfections acquired at different times during the Phd work. The test set consisted of
eight images where four contained brains with poor tissue clearing and the other four contained brains
scanned with a lower quality light sheet arising from poor operator settings. Examples of segmenta-
tion results obtained with the rNGF-based AMM and the SSD-based AAM are seen in Fig. 9.1a. The
SSD-based model fails to segment the VL in case of the lower quality light sheet. Dice scores of the
individual brain structures are seen in Fig. 9.1b. The rNGF-based model results in higher Dice scores
and less variance.
Going forward the AAMs could be extended to 3D and potentially be used to segment individual brain
regions as a complementary method to the image registration approach. A challenge is the need for
manual annotated training data which is a work intensive and difficult task in 3D. Another idea could
be to use rNGF as similarity measure during the 3D atlas registrations since the similarity measure in
this work showed favorable in the analysis of LSFM images.
Figure 9.1: (a) Examples of segmentations obtained with rNGF-based model (top) and SSD-based
model (bottom row). Images shows a brain recorded with lower quality light sheet. (b)
Boxplot of Dice scores of the individual segmented structures. The median is represented
as the center line of each box and the edges correspond to the 25th and 75th percentiles.
Chapter 10
Conclusions
The aim of the PhD project was to develop algorithms to enable automated high throughput quantifi-
cation of whole brain LSFM data. This was accomplished by utilizing image registration to integrate
the LSFM data with the CCFv3 digital brain atlas from AIBS. The LSFM system has been used to
image distribution of fluorescently labelled peptides as well as brain receptor localization and brain
activation in response to treatment with the peptides. During the project the methodology expanded
to also include integration of information from user 2D histology sections and brain connectivity maps
from AIBS. The developed atlas was used to investigate CNS biology related to GLP-1RAs and leptin.
GLP-1R was mapped in the mouse brain and showed a broad distribution. It was observed that
fluorescently labelled liraglutide accessed a subset of these receptors after peripheral administration.
Distribution was seen in hindbrain, hypothalamus, and cerebral nuclei. Peripheral administration of
liraglutide led to brain activation in regions previously related to decreased food intake. A comparison
between the observed brain activation and the distribution of fluorescently labelled liraglutide led to
a hypothesis of direct activation by liraglutide in the hindbrain. A comparison between the observed
brain activity and connectivity maps from AIBS led to a hypothesis of secondary brain activation
relayed by the PB.
LebRb was mapped in the mouse brain and like GLP-1R showed a broad distribution. Brain ac-
tivation in response to peripheral leptin treatment peaked between 60 minutes and 120 minutes in
lean mice. The strongest brain activation was observed in the hypothalamus. Brain activation in
response to leptin treatment was compared in lean mice and obese phenotypes. Leptin treatment led
to a large increase in brain activation in lean mice compared to baseline, but failed to do so in DIO mice.
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Going forward there are many opportunities to further improve the developed integrated brain at-
las. Improvements may be achieved regarding both tissue preparation protocols, image acquisition
protocols, and developed algorithms. The atlas could further be improved by integrating data from
additional sources. One example could be gene expression data from AIBS. By testing additional
antibodies with whole brain IHC staining in combination with LSFM it will also be possible to add
information about other relevant receptors and activation markers related to brain control of body
weight and appetite regulation. Integration and analysis of these data has the opportunity to aid in
the development of improved treatment options for people with obesity.
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Light Sheet Fluorescence Microscopy (LSFM) of whole organs, in particular the brain, offers a plethora of 
biological data imaged in 3D. This technique is however often hindered by cumbersome non-automated 
analysis methods. Here we describe an approach to fully automate the analysis by integrating with data from 
the Allen Institute of Brain Science (AIBS), to provide precise assessment of the distribution and action of 
peptide-based pharmaceuticals in the brain. To illustrate this approach, we examined the acute central nervous 
system effects of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide. Peripherally administered 
liraglutide accessed the hypothalamus and brainstem, and led to activation in several brain regions of which 
most were intersected by projections from neurons in the lateral parabrachial nucleus. Collectively, we provide 
a rapid and unbiased analytical framework for LSFM data which enables quantification and exploration based 
on data from AIBS to support basic and translational discovery. 
  
Introduction 
Light Sheet Fluorescence Microscopy (LSFM) is an imaging 
system with high sensitivity, micrometer resolution, and short 
acquisition time enabling imaging of a whole mouse brain in 
less than one hour
1
. This technology was previously used to 
evaluate the access of fluorescently labelled peptides from the 
periphery to the brain
2
. Quantification of the 3D brain 
distribution by manual annotation however is a slow process 
hindering high-throughput analysis of the large data sets.  
Recently, it was shown how the Common Coordinate 
Framework version 3 (CCFv3) of the Allen Institute for Brain 
Science (AIBS) can be utilized to automatically perform 
quantitative analysis of LSFM data based on image 
registration
3,4
. In the work by Reiner et al.
3
, the authors used 
the digital CCFv3 atlas as basis for quantifying whole brain 
activity by automated analysis of immediate early genes such 
as c-Fos. A similar strategy for mapping c-Fos activation using 
image registration was performed by Kim et al.
5
. Here, we 
present a similar image registration approach, which extends 
the automated analysis further by utilizing the multi-modality 
nature of the AIBS atlas, which besides an average mouse brain 
template based on tissue auto-fluorescence
6
 also contains an 
aligned histology-based template constructed from Nissl-
stained brain sections
7
. This enables mapping of 3D 
information from LSFM together with 2D information from 
histological techniques such as in situ hybridization (ISH), for 
direct data comparison. In this manuscript we utilized LSFM to 
map brain distribution of fluorescently labelled peptides as 
well as whole brain c-Fos activation. ISH was used to map the 
localization of the peptide’s endogenous receptor. 
The AIBS data portal contains impressive amounts of open 
science data including expression patterns of approximately 
20,000 genes in the adult mouse brain
7
, and a brain-wide, 
cellular-level, mesoscale connectome for the mouse describing 
neural connectivity between brain regions
6
. Scientists at AIBS 
have mapped these data to the CCFv3 atlas for efficient online 
browsing and quantification. However, using the online tools 
there is no method to automatically compare data from user 
experiments with content from the AIBS data portal, 
presenting an unmet need. Our integrated brain atlas 
approach allows the researcher to download data sets from 
the AIBS data portal and directly integrate with user LSFM 
experiments. Thousands of high-resolution connectivity maps 
of neural connections in the mouse brain from a range of 
mouse lines are hence available for direct numerical 
comparison with the user LSFM data. Together, our integrated 
atlas approach provides a high throughput setup allowing 
automated comparison and quantification of peptide brain 
access, receptor expression, cell activation, and brain 
connectivity. 
The glucagon-like peptide-1 receptor agonist (GLP-1RA) was 
chosen as a model drug to highlight the possibilities with our 
novel analysis approach. Liraglutide is a GLP-1RA approved and 
widely used for the treatment of diabetes
8
, and is also 
approved as a treatment option for weight management, 
reducing appetite and body weight following peripheral once-
daily administration
9
. It has been shown that GLP-1RAs act on 
peripheral organs but also target GLP-1 receptors (GLP-1R) in 
the brain. The brain actions of liraglutide are thought to 
contribute in large part to the weight loss effect
2,10
. Here, we 
first mapped the brain distribution of fluorescently labelled 
liraglutide following peripheral injection.  The brain 
distribution signal was compared to the location of glp-1r 
expressing cells, pointing to potential peptide targets 
throughout the brain. Brain activation in response to 
peripheral administered liraglutide was quantified by mapping 
whole brain c-Fos activation compared to vehicle dosed 
controls. To increase the understanding of the activated neural 
networks the c-Fos findings were compared with neural 
connectivity maps from the AIBS data portal. Comparing the 
connectivity maps with liraglutide induced c-Fos increase, 
showed a robust correlation of activation cascades involving 
projections from the parabrachial nucleus (PB). Collectively, 
the integrated brain atlas approach combined with easy-to-use 
visualization tools and quantification model was shown to 
enable high-throughput studies aiming to investigate peptides 
with brain mode-of-action. 
Results 
Integrated brain atlas. The CCFv3 from AIBS was used as basis 
for constructing an integrated brain atlas to enable 
quantification and comparison of data regarding brain access, 
receptor location, neural activity, and brain connectivity. The 
atlas implementation combines user data from LSFM and 
histology, as well as connectivity maps downloaded from the 
AIBS data portal (Fig. 1a-c).  LSFM was used to image in vivo-
dosed fluorescently labelled peptides as well as whole brain 
immunohistochemistry (IHC) showing c-Fos activation. 
Histology was used to map glp-1r expressing cells using in situ 
hybridization (ISH).  Alignment to the integrated brain atlas 
was performed using the image registration software Elastix
11
 
using affine and b-spline transformations for each of the larger 
brain structures (Supplementary Fig. 1). For exploration 
purposes, all mapped data were imported into a commercially 
available software program allowing visualization of 3D 
maximum intensity projections as well as sagittal, horizontal, 
and coronal 2D projection images (Fig. 1d). Visual comparisons 
of results from different experiments were achieved by 
constructing average 3D signals combining individual brain 
samples, and overlaying these resulting average signals onto 
the CCFv3 template (Fig. 2). The average brain signals provide a 
compact representation of the raw data, which can be easily 
stored and later compared to future experiments. Automatic 
extraction of statistical measures in brain regions of interest 
was performed using the annotated model of the CCFv3 (Fig. 
1e). Data presented in the following result sections were all 
automatically mapped to the integrated brain atlas enabling 
combined visualization and quantification (Fig. 1f).
Figure 1 I Multi-modality brain atlas integrating information from user data and AIBS data portal. (a) LSFM data showing brain 
distribution of labelled peptides (pink), as well as brain activation patterns (blue) using whole brain IHC staining for c-Fos. Top left 
drawing shows a mouse brain (yellow) imaged by a light sheet (green). (b) Histology data showing receptor location based on in situ 
hybridization (ISH).  (c) Connectivity maps from the AIBS data portal
6
. Left: example of injected viral tracer. Right: Colored circles 
indicating the primary injection site of each experiment. (d) Screen shots from a commercial 3D image rendering software used to 
explore overlay images of data mapped to the integrated brain atlas. (e) Illustration showing that all mapped data can be quantified 
automatically using the annotation of the CCFv3. The graph data is from Fig. 2b. (f) Illustration of the integrated brain atlas allowing 
quantification and comparison between experiments from different image modalities and labelling techniques. Data can be easily 
navigated as maximum intensity projections (3D) or orthogonal projections (2D).  
 
Figure 2 I Average brain signals. (a) Example of maximum intensity projection images created from four individual brains from mice 
injected I.V. with liraglutide
VT750
. The brains were registered to the atlas space and a voxel-wise average distribution signal 
representing the experiment group was computed.  (b) The average signal from (a) overlaid onto the CCFv3 template.   (c) Coronal 
projection images constructed from (b). The color map was adjusted by a factor 2.5 in the top row to ease visualization of the lower 
signals in the non-circumventricular regions compared to the higher signals in the circumventricular regions (bottom row). 
Fluorescently labelled liraglutide distributes to regions in 
hypothalamus and brainstem following peripheral 
administration. GLP-1 is an incretin hormone, physiologically 
released from intestinal L-cell in response to food intake, but 
also produced and released as a neurotransmitter mainly from 
hindbrain neurons
12
. As the GLP-1R distribution is abundant in 
the brain
13,14
, we first sought to investigate which brain regions 
had access to the GLP-1RA liraglutide when injected 
peripherally. VivoTag-S®750 labelled liraglutide 
(liraglutide
VT750
) previously used to investigate brain access
2
 
was administered intravenously in C57BL/6J mice and 
compared to vehicle dosed controls. The observed 
liraglutide
VT750
 signals were mapped to the integrated brain 
atlas, and the total fluorescence signal in selected regions was 
quantified (Fig. 3c). The analysis was enabled by registration of 
the auto-fluorescence channel of the LSFM acquisition to the 
CCFv3 template allowing quantification of the specific 
liraglutide
VT750
 signal using the atlas annotations (Fig. 3a-b). 
Using the nomenclature of the AIBS mouse brain atlas, 
liraglutide
VT750
 was significantly detected in circumventricular 
organs (CVOs) such as area postrema (AP) and vascular organ 
of the lamina terminalis (OV), as well as in regions shielded by 
the blood brain barrier (BBB) such as arcuate hypothalamic 
nucleus (ARH), paraventricular hypothalamic nucleus (PVH), 
and Supraoptic nucleus (SO). Liraglutide
VT750
 was also observed 
in the choroid plexus (chpl), exemplified by the plexus located 
in the fourth (V4) and lateral (VL) ventricle. To validate the 
findings another group of C57BL/6J mice were dosed with cy3 
labelled liraglutide and the brains were processed for confocal 
microscopy (Fig. 4). In general there was good agreement of 
targeted brain regions detected using the two different 
methods, except in NTS, DMX, and SF, where significantly 
lower signals were observed with confocal microscopy.  To 
visualize the brain distribution of liraglutide
VT750
 an average 
distribution signal was computed and imported into the 
integrated brain atlas (Fig. 3d).  It was observed that many 
regions with liraglutide
VT750
 access were in near proximity of 
the CVOs which contain fenestrated capillaries allowing free 
access of blood borne molecules. To elaborate on this, the 
distance from the CVOs to the complete liraglutide
VT750
 
distribution was evaluated. This was performed by peripheral 
administration of fluorescently labelled MECA-32 antibody, 
which exclusively labels the fenestrated capillaries
15
. Figure 5 
shows a maximum intensity projection of the MECA-32
VT750
 
signal in the brain, together with a distance map constructed 
by computing the distance from any voxel in the integrated 
brain atlas to the nearest voxels containing MECA-32
VT750
 
signal. The distance map was used to quantify the relationship 
between liraglutide
VT750
 and the fenestrated capillaries. The 
distances in most regions were small suggesting diffusion or 
integrated uptake of the labelled liraglutide following access 
through fenestrated capillaries.  However, the distances in 
PVH, SO, and TU were significantly larger suggesting another 
mechanism of access to these regions.
 
Figure 3 I Brain regions with liraglutide
VT750
 access. (a) 2D coronal projections from data acquired with LSFM following liraglutide
VT750
 
administration in C57BL/6J mice. The specific signal was mapped to the integrated brain atlas for quantification following auto-
fluorescence background reduction by spectral unmixing. (b) 2D projection showing a mapped liraglutide
VT750 
signal overlaid onto the 
CCFv3 atlas template. Automated quantification was achieved using the corresponding annotations. (c) Bar graph showing the mean 
fold change and standard deviation (SD) of the total fluorescence signal in selected brain regions comparing liraglutide
VT750
 and vehicle 
(n=5). An asterisk marks significant difference between treatments when analyzed in individual brain regions using a false discovery rate 
value of 5% to correct for multiple comparisons. Note the split y-axis when interpreting results and standard deviations. See 
Supplementary Table 1 for full brain region names. (d) Maximum intensity projection of the average liraglutide
VT750
 signal computed 
from the individual brains in the study group (n=5).
 
Figure 4 I Confocal images of liraglutide
Cy3
. Overview of liraglutide
Cy3
 in the mouse brain. High magnification confocal images from mice 
injected with liraglutide
Cy3
. Brain regions where liraglutide
Cy3
 (red) stained with DAPI nuclear stain (blue) were observed, compared to 
the corresponding region from an animal injected with vehicle (PBS). 
 Figure 5 I Distance map calculations. (a) Fenestrated capillaries visualized by maximum intensity projection of a MECA-32
VT750
 brain 
signal overlaid onto the CCFv3 template. (b)  Maximum intensity projection of average liraglutide
VT750
 signal (n=5) overlaid onto the 
CCFv3 template. (c) Coronal projection of the MECA-32
VT750
 signal registered to the atlas space and overlaid onto the CCFv3 template. 
(d) Distance map constructed from the MECA-32
VT750
 signal. The value at a given voxel was assigned as the shortest Euclidian distance to 
a voxel classified as MECA-32
VT750
 positive. Blue indicate voxels close to fenestrated capillaries, while yellow indicate voxels far from 
fenestrated capillaries. (e) Average liraglutide
VT750
 signal overlaid onto a coronal section of the CCFv3 template. (f) Center of mass 
distances computed for the liraglutide
VT750
 signals described in Fig. 3. The computation was performed in the brain regions marked for 
discovery in Figure 3c. 
Aligning histology and LSFM data highlights possible direct 
targets of liraglutide. To have a direct brain effect the 
administered liraglutide must activate its receptor, the GLP-1R. 
To further elaborate the relevance of the brain distribution of 
liraglutide
VT750
 a comparison was made between the average 
distribution signal and cells expressing glp-1r mRNA. The ISH 
platform RNAscope
16,17
 was used to map the glp-1r mRNA 
location in a number of coronal slides throughout the C57/BL6 
mouse brain. To enable direct comparisons of images from 2D 
histology with 3D LSFM imaging (Fig. 6a), a heat map was 
computed from the ISH section to represent the glp-1r positive 
cells. The heat map was aligned to the integrated brain atlas, 
which enabled direct visual comparison with the average 
liraglutide
VT750
 distribution from Figure 3d.  An example of a 
mapped glp-1r ISH heat map compared to the corresponding 
anatomical location in the average liraglutide
VT750
 distribution 
signal is seen in Fig. 6b.  In this anatomical location the 
liraglutide
VT750
 distribution signal overlapped with the glp-1r 
signal in SO and SFO, while a liraglutide
VT750
 signal was also 
observed in the chpl located in VL where no receptor signal 
was present. Receptor expression was observed in Lateral 
septal nucleus (LS), Substantia innominata (SI) and the anterior 
part of PVH without a corresponding liraglutide
VT750
 signal. 
More glp-1r ISH images were obtained for regions with 
liraglutide
VT750
 access (Fig. 7). Comparing to the statistical 
significant brain regions with liraglutide
VT750
 access (Fig. 3c), 
glp-1r was detected in ARH, DMH, PVH, OV, PVp, SO, TU, AP, 
and NTS providing possible direct targets of liraglutide. To 
further investigate liraglutide
VT750
 interaction with the GLP-1R 
a group of Glp-1r
-/-
 mice was studied. In parallel to the 
liraglutide
VT750
 distribution study presented in the previous 
section, liraglutide
VT750
 was injected in Glp-1r
-/-
 mice devoid of 
a functional GLP-1R. Visual and quantitative comparisons of 
the distribution signals showed a large decrease of signal in the 
knockout mice, in all brain regions except for the choroid 
plexus (Fig. 8). Together with the histology findings, this 
indicated a specific GLP-1R dependent localization of 
liraglutide
VT750
 in the brain.
 
Figure 6 I Comparison of glp-1r localization and average liraglutide
VT750
 distribution. (a) Concept behind aligning a 2D histology image 
(right) with 3D LSFM data (left). A histology image was aligned to an interpolated section of the integrated brain atlas template. Once 
aligned a similar interpolated projection from the average liraglutide
VT750
 distribution signal could be generated. Example ISH section 
with zoom panel at SO region. Red color indicates cells positive for glp-1r. (b) Heat map (blue) representation of ISH section from Fig. 
6a aligned with the average liraglutide
VT750
 signal (pink) from Fig. 3d. The signals are overlaid onto separate halves of the CCFv3 
template. 
 Figure 7 I Enhanced ISH images. Images show glp-1r expression in targeted brain regions. Overview of the glp-1r mRNA localization in 
a number of coronal sections throughout the C57/BL6 mouse brain. High magnification slide scanner images from untreated mice.  
Panel shows selected brain regions with glp-1r mRNA (red) counter stained with Mayer’s hematoxylin (blue).  
 
Figure 8 I Liraglutide
VT750 
in wild type vs Glp-1r
-/-
 mice. (a) Maximum intensity projection of average liraglutide
VT750
 signal following 
administration in Glp-1r
-/-
 animals overlaid onto the CCfv3 template. (b) Maximum intensity projection of liraglutide
VT750 
signal 
following administration in wild-type animals overlaid onto the CCfv3 template. (c) Bar graph showing mean fold change and 
standard deviation of vehicle normalized signals (total fluorescence) from liraglutide
VT750 
injected wild-type (WT)  and Glp-1r
-/-
 (KO) 
animals. See Supplementary Table 1 for full brain region names. 
Whole brain c-Fos staining shows that liraglutide activates 
brain regions related to food intake. GLP-1RAs are known to 
reduce appetite following peripheral administration, and this 
effect has been linked to both hypothalamic and hindbrain 
action
2,18
. To investigate changes in brain activity following 
peripheral administration of liraglutide, C57BL/6J mice were 
dosed subcutaneously with liraglutide, and the c-Fos response 
was compared to vehicle dosed controls. c-Fos staining was 
performed on intact brains using the iDISCO protocol
19
, and 
brains were subsequently scanned using LSFM. The most 
prominent c-Fos increase following liraglutide injection was 
seen in Bed nuclei of the stria terminalis (BST), Paraventricular 
nucleus of the thalamus (PVT), Central amygdala nucleus 
(CEA), Parabrachial nucleus (PB), and NTS (Fig. 9a). To evaluate 
the whole brain c-Fos response, heat maps were computed for 
each individual brain sample based on the amount of c-Fos 
positive cells, and these heat maps were registered to the 
integrated brain atlas (Fig. 9b). The heat maps were used to 
quantify the differences between liraglutide and vehicle dosed 
animals in select brain regions (Fig. 9c). To investigate whether 
the observed c-Fos response could be a direct effect of 
liraglutide interaction with GLP-1R we visually compared the 
liraglutide specific c-Fos increase with the liraglutide
VT750
 
distribution from Fig. 3d.  This was enabled by first computing 
the average c-Fos response from the liraglutide and vehicle 
group separately (Fig. 9d), followed by voxel wise subtraction 
of the vehicle response from the liraglutide response. The 
liraglutide specific c-Fos increase was then imported into the 
integrated brain atlas to allow direct overlay with the average 
liraglutide
VT750 
distribution signal (Fig. 9e, Supplementary 
movie 1). Some overlap was seen, mainly in AP, but also in ARH 
and OV indicating possible direct activation from liraglutide in 
these regions. However, the majority of c-Fos increase 
occurred in regions not directly targeted by liraglutide
VT750
, 
indicating secondary activation. Figure 10 shows a rank plot 
comparing the ranks from lowest to highest fold change of 
data presented in Fig. 3c and Fig. 9c to give a further overview 
of brain regions with possible direct and secondary activation. 
c-Fos increase but no liraglutide
VT750
 signal, indicating 
secondary activation, was seen in BST, PVT, PB, and CeA which 
are regions previously described to be related to lowering of 
food intake
19,21
. Liraglutide specific c-Fos increase was also 
observed in the motor neurons receiving input from the vagus 
nerve. 
Comparing c-Fos increase with AIBS connectivity maps 
suggests that activation may involve a common parabrachial 
pathway. The fact that the majority of induced brain activity 
seen by c-Fos increase was observed in brain regions not 
directly targeted by liraglutide
VT750
 likely indicates that neurons 
in these regions responded as part of larger neural networks. 
We hypothesized that these regions were part of networks 
related to appetite regulation and feeding behaviour. To 
investigate this hypothesis the complete set of grey matter 
connectivity maps were downloaded from the AIBS data portal 
(2469 experiments) and mapped together with the liraglutide 
specific c-Fos increase. The 2469 connectivity maps were 
automatically ranked by the amount of overlap with the c-Fos 
increase, taking into account the total overlap of the c-Fos 
signal  and given connectivity signal in relation to the amount 
of c-Fos signal not overlapping with the given connectivity 
signal and vice versa (Fig. 11a).  Supplementary Table 2 lists 
the 30 most overlapping connectivity maps compared to the 
liraglutide specific c-Fos increase. Based on the automated 
ranking, the most overlapping connectivity map was 
projections from Rasgrf2 (Rasgrf2-2A-dCre) positive cells in the 
NTS. In addition, several neuronal subpopulations previously 
described to decrease food intake were observed among the 
highest ranking connectivity maps. Projections from 
proopiomelanocortin (POMC) positive neurons (Pomc-Cre (BL)) 
in the ARH were ranked as the 29
th
 most overlapping 
connectivity map, and targeting of this neuronal subpopulation 
has previously been shown following GLP-1RA stimulation
2
. 
Projections from PKC-delta+ positive neurons in CEA were 
ranked as the 15th most overlapping connectivity map. PKC-
delta+ is a neuronal subpopulation which has previously been 
described to influence anorexigenic signals in combination 
with the lateral PB
21
.   Based on the automated ranking, 
projections from the lateral PB were seen in four of the ten 
most overlapping connectivity maps compared to the 
liraglutide specific c-Fos increase. As liraglutide
VT750
 showed no 
significant access in the PB, this suggests a role of the PB as a 
relay station of input from other targeted brain regions. 
Glutamatergic (slc17a6-IRES-Cre) projections from the lateral 
PB (4
th
 most overlapping connectivity map) and PKC-delta+ 
(Prkcd-GluCla-CFP-IRES-Cre) projections from the CEA were 
imported into the integrated brain atlas to visualize how these 
neurons could be part of the activated c-Fos response 
following liraglutide treatment (Fig. 11b-d, Supplementary 
movie 2). This parabrachial pathway has in recent literature 
been described as a general circuit causing anorexia
18,21,26
, and 
here also appears to be involved in the acute brain activation 
of liraglutide.
   
 Figure 9 I Neural activation following liraglutide administration. (a) Example images of c-Fos response in liraglutide vs vehicle dosed 
C57BL/6J mice. Bregma coordinates denote the anatomical location. (b) c-Fos heat map computed from one liraglutide injected 
mouse. See also Supplementary Figure. 3. (c) Bar graph showing the mean fold change and standard deviation (SD) of total c-Fos heat 
map signal in selected brain regions comparing liraglutide and vehicle dosed animals. Regions were selected as having either 
liraglutide
VT750
 access, GLP-1R expression, or c-Fos response. An asterisk marks significant difference between treatments when 
analyzed in individual brain regions using a false discovery rate value of 20% to correct for multiple comparisons. See Supplementary 
Table 1 for full brain region names.  (d) Computed average c-Fos signal from liraglutide injected animals (left), and vehicle injected 
animals (right). (e) Liraglutide specific c-Fos increase overlaid with the average liraglutide
VT750
 distribution from Fig. 3d.
 Figure 10 I Rank plot. Rank plot comparing c-Fos activation data from Figure 9c with liraglutide
VT750
 distribution data from Figure 3c. 
The brain regions were ranked based on their fold change value and these rankings were used as x and y coordinates in the plot. Top 
right corner contains brain regions where a direct activation from liraglutide is most plausible. 
 
Figure 11 I Comparing brain connectivity maps with whole brain c-Fos data. (a) Left to right: Horizontal projection image of average c-
Fos increase following liraglutide administration; example of corresponding horizontal projection of downloaded connectivity map; 
overlap signal between c-Fos signal and connectivity signal; total signal of c-Fos signal and connectivity signal. (b) Bottom: Part of 
primary injection site (PB) in a slc17ac cre mouse. Top: part of primary injection site (CEA) in a Prkcd-GluCla-CFP-IRES-Cre mouse. 
Data was downloaded from the AIBS data portal. (c) Connectivity maps visualized by maximum intensity projection overlaid with the 
average c-Fos increase following liraglutide administration. Left: sagittal maximum intensity projection; right: horizontal maximum 
intensity projection. (d) Coronal projection images showing downloaded glutamatergic projections from PB, and PKD-delta+ 
projections from CEA, together with the average c-Fos increase following liraglutide administration. Signals are overlaid onto the 
CCFv3 template.
Discussion  
In this manuscript a novel analysis approach was presented, 
combining data from numerous sources in an integrated brain 
atlas including data from LSFM imaging, histology, and data 
from AIBS. LSFM imaging is high throughput with data 
acquisition times in the range of one hour for a whole mouse 
brain. The automated analysis approach enables the 
researcher to gain the advantages of this high throughput 
LSFM imaging system by removing the bottleneck arising from 
manual analysis of the large data sets. By registering the 
acquired whole brain data with the CCFv3 atlas from AIBS, the 
user can additionally align LSFM data with standard histological 
images, as well as automatically compare LSFM data to 
connectivity maps from the AIBS data portal. By combining the 
different imaging technologies the distribution of bioactive 
peptides can be correlated to the peptide’s endogenous 
receptor, changes in brain activity, and connectivity between 
relevant brain regions. This provides mechanistic information 
that would not be afforded by a single technology alone. 
Furthermore, importing all experiment data to a common 
reference atlas effectively allows the user to build an 
anatomical database of information which can be compared to 
parallel and future studies, thereby increasing the value of 
each experiment.  
To highlight the possibilities with this novel analysis approach 
the acute brain effect of the GLP-1RA liraglutide was 
investigated. In agreement with previous observations
2
, 
liraglutide
VT750
 had access to the chpl, the CVOs, and regions 
shielded by the BBB such as ARH, PVH, SO, and TU. It should be 
noted that the observed liraglutide
VT750
 signals in regions close 
to the CVOs may have been overestimated due to the 
thickness and beam profile of the light sheet in the LSFM 
system. This was the case for the brain regions NTS, DMX, and 
SF comparing to detection with confocal microscopy. To 
minimize this issue work is needed concerning deconvolution 
algorithms for LSFM systems. The issue was much less 
pronounced in the c-Fos studies as the fluorescence signals 
here were much more uniform and confined to the cell bodies. 
By computing the distance between the fenestrated capillaries 
and the average liraglutide
VT750
 distribution, it was seen that 
the peptide likely could access the brain either by diffusion 
from the CVOs or by uptake through specialized cell structures 
intercepting the BBB protected brain regions with the CVOs.  
Examples of such cells are tanycytes which have previously 
been demonstrated to mediate uptake of other peripheral 
peptides in the ARH
22
. Glp-1r expression was observed in most 
brain regions with liraglutide
VT750
 access indicating that the 
observed liraglutide
VT750
 distribution signal was GLP-1R 
dependent. This was confirmed by a decreased brain 
distribution signal of liraglutide
VT750
 observed in Glp-1r
-/-
 mice. 
Changes in brain activation following an acute subcutaneous 
injection of liraglutide were investigated by whole brain c-Fos 
staining. Visually the most prominent increases were seen in 
BST, PVT, CEA, PB, and NTS, while quantitative analysis also 
showed a significant increase in AP and ARH. Comparing the c-
Fos increase to the liraglutide
VT750
 distribution it was possible 
that liraglutide directly activated GLP-1R in AP and ARH. c-Fos 
signal could not be observed in some regions with strong 
liraglutide
VT750
 signal such as SO, TU and SFO. Although not 
demonstrated before, this could be due to time related 
differences in protein activation of primary versus secondary 
activation sites or negative activation profiles counteracting 
the signal. As c-Fos is a marker for increased neuronal activity 
it is also possible that some of the effect of liraglutide is 
inhibitory, and hence not detected by the c-Fos analysis. A 
comparison between the liraglutide
VT750
 distribution signal and 
the liraglutide specific c-Fos increase showed that the majority 
of brain activation was likely to be secondary events. To 
understand the secondary c-Fos activation 2469 connectivity 
maps from the AIBS data portal were downloaded and added 
to the integrated brain atlas. Projections from ras-specific 
guanine-nucleotide releasing factor 2 (Rasgfr2) positive cells in 
NTS were ranked by automated computations as the most 
overlapping connectivity map comparing to the liraglutide 
specific c-Fos increase. Previous work indicates a role for 
Rasgfr2 in the regulation of mesolimbic dopamine neuron 
activity
23
. However, to the best of our knowledge no direct 
links has been established with appetite or body weight 
regulation. A strong correlation between c-Fos activation and 
connectivity maps were also seen with projections from the 
lateral PB exemplified by glutamatergic projections (slc17a6 
cre). Recent work
18,24-26
 describes the role of the lateral PB as a 
conduit for visceral signals that cause anorexia. The lateral PB 
has also been shown to be necessary for the acute reduction in 
food intake by another GLP-1RA exendin-4 in rats
27
. The lateral 
PB is a site of integration of satiety signals from the brainstem, 
but other neurons also projects to this region such as agouti-
related protein AGrP and POMC positive neurons from the 
ARH. This suggests an interconnection between brainstem and 
hypothalamus input in the control of feeding.  Direct 
projections from POMC positive neurons in the ARH also 
showed a general overlap with the liraglutide specific c-Fos 
increase, although to a lesser degree compared to projections 
from the lateral PB.  
As all experiments were registered to a common atlas space 
the quality of subsequent data analysis was dependent on the 
registration quality. The 3DISCO clearing protocol
28
 was used 
prior to LSFM imaging which was previously reported to 
introduce non-uniform tissue shrinkage
3
. To mitigate the 
effects of the non-uniform tissue shrinkage a registration 
model which allowed different degrees of shrinkage in each of 
the larger brain structures was introduced.  The registration 
accuracy was tested by manually placing landmarks in the atlas 
template and comparing these to corresponding landmarks 
placed in a test set of registered brain samples. The average 
error between corresponding landmarks was approximately 5 
voxels equal to 100 μm (Supplementary Fig. 2). The LSFM 
system acquires high resolution images from which lower level 
representations such as average distribution signals and c-Fos 
heat maps of brain activity were computed. These 
representations enabled direct visual and quantitative 
comparisons of results from parallel experiments. Overall, the 
developed analysis approach provides a strong foundation for 
anatomical studies and could be a valuable tool in combination 
with functional studies going forward. The high throughput 
approach enables automated analysis of user experiments 
based on large scale data from AIBS, and by integrating these 
data the goal is to discover new knowledge otherwise hidden 
in the large complexity of the brain. 
 
 
Methods 
Animals. All in vivo studies were conducted in accordance with 
approved national regulations in Denmark, which are fully 
compliant with internationally accepted principles for the care 
and use of laboratory animals, and with animal experimental 
licenses granted by the Danish Ministry of Justice. Animals 
were obtained from Taconic, Denmark and housed in standard, 
temperature-controlled conditions with a 12-hour-light/dark 
cycle. The animals had ad libitum access to water and regular 
chow. 
Distribution of liraglutide
VT750
. Fluorescently labelled 
liraglutide was synthesized by conjugating VivoTag-S®750 NIR 
FLUOROCHROME LABEL (Perkin Elmer) to the liraglutide 
peptide. Liraglutide
VT750
 (30 nmol/kg) or vehicle (PBS) were 
injected I.V. into male (n=6) C57BL/6J wild type and Glp-1r
-/-
 
mice, and left to circulate for 6 hours in the animals. The mice 
were euthanized using cardiac perfusion with 10% neutral 
buffered formalin (NBF), followed by overnight fixation in NBF 
at room temperature overnight, and subsequently cleared 
using the 3DISCO protocol
28
. 
Distribution of liraglutide
Cy3
. Fluorescently labelled liraglutide 
was synthesized by conjugating Cyanine 3 (Cy3) (Lumiprobe) to 
the liraglutide peptide. Liraglutide
Cy3
 (120 nmol/kg) or vehicle 
(PBS) were injected I.V. into male (n=3) C57Bl/6J mice and left 
to circulate for 6 hours in the animals. The mice were 
anesthetized using isoflurane, and euthanized using cardiac 
perfusion with first saline followed by 4% paraformaldehyde 
(PFA), the brains were then collected and post fixated in 4% 
PFA at room temperature overnight. After post fixation, the 
brains were transferred to 25% sucrose solution, once the 
brains had descended to the bottom of the well they were 
sectioned coronally using a cryostat at 35 µm and collected in 
6 series. One series from each mouse was stained with DAPI 
(1:1000). Confocal images from various brain regions were 
acquired using a Leica SP8 (Leica DMi8). 
Distribution of MECA-32
VT750
. Fluorescently labelled MECA-32 
antibody was synthesized by conjugating VivoTag-S®750 NIR 
FLUOROCHROME LABEL (Perkin Elmer) to the MECA-32 
antibody (BE0200) from BioXCell. MECA-32
VT750
 (0.2 mg/kg) 
were injected I.V. into male (n=2) C57BL/6J wild type mice, and 
left to circulate for 6 hours in the animals. The mice were 
euthanized using cardiac perfusion with 10% NBF, followed by 
overnight fixation in NBF at room temperature overnight, and 
subsequently cleared using the 3DISCO protocol
29
. 
Whole brain c-Fos staining. C57Bl/6J male mice were 
subcutaneously injected with liraglutide (0.4 mg/kg) or vehicle 
(n=6). Mice were euthanized 4 hours after injection using 
isofluorane followed by cardiac perfusion with 4% 
paraformaldehyde.  Brains were excised and post fixed in 4% 
paraformaldehyde overnight at room temperature and 
transferred stepwise to 100% methanol using the following 
protocol. 20% methanol (in ddH2O) for 1h, 40% methanol for 
1h, 60% methanol for 1h, 80% methanol for 1h, and 100% 
methanol for 1h twice. iDISCO staining was performed as 
described in Renier et al.
19
 with one exception. All the washing 
steps after incubation with primary and secondary antibody 
were extended from one to three days. Incubation time for 
primary and secondary antibody was 4 days each. The primary 
antibody was Rabbit pAb anti c-Fos (Ab-5) (4-17) from 
Calbiochem (1:10,000 dilution), and the secondary antibody 
was Cy5-anti rabbit from Jackson Immunoresearch (1:1000 
dilution). 
Light sheet imaging. Brain samples were scanned using an 
UltraMicroscope II LSFM system (Lavision Biotec, Bielefeld, 
Germany) in 10.32 μm isotropic resolution for the 
liraglutide
VT750
 distribution study, and 4.06 μm for the c-Fos 
activation study. For labelled peptides data acquisition was 
performed using a 620 nm emission filter for imaging auto-
fluorescence, and a 710 nm emission filter for imaging specific 
signals. With whole brain c-Fos staining the auto-fluorescence 
was recorded at 545 nm, while the c-Fos signal was acquired 
with a 620 nm emission filter. 
RNAscope ISH. C57Bl/6J male mice (n=2) were perfused and 
post-fixed as described previously
29
 and tissues were 
subsequently paraffin-embedded and sectioned at 5 μm 
intervals. Automated ISH was performed on a Ventana 
Discovery ULTRA following the technical bulletin provided by 
ACD Bio (#322250-USM-ULT). Our assay utilized the Ventana 
mRNA RED Detection Kit (Roche, #7074654001), RNAscope 
RED kit (ACD Bio, #322250), and the following oligonucleotide 
probes from ACD Bio: Mm-Glp1r (#418859), Mm-Polr2a 
(#312479), Mm-NPY (#313329), and dapB (#312039). Mm-
Polr2a and Mm-NPY served as positive controls, and dapB was 
used as a negative control. ISH sections were subsequently 
counterstained in 30 dips of Mayer’s hematoxylin, 
coverslipped, and scanned on a Zeiss AxioScan at 40x 
magnification. To assist in aligning ISH data with the integrated 
brain atlas, Nissl staining (0.1% w/v cresyl violet with 0.5% v/v 
glacial acetic acid, 5 minute incubation) was performed on 
adjacent brain sections from each series of tissue collected for 
ISH. 
Image analysis. Images were registered using the Elastix 
software library
11
. A source image IS(x) was registered to a 
target image IT(x) by finding a coordinate transformation T(x) 
that made IS(T(x)) spatially aligned with IT(x). We used an affine 
coordinate transformation for initialization followed by non-
rigid b-spline coordinate transformation which was iteratively 
optimized with respect to the mutual information between the 
source and the target. Registration parameters for mapping of 
LSFM data were similar to those used in Renier et al.
3
. 
Parameters for registration of histology sections were similar 
to those used in Abdelmoula et al.
30
. Spectral unmixing was 
performed to minimize the contribution of tissue auto-
fluorescence in the liraglutide
VT750
 distribution study. The 
estimated auto-fluorescence contribution in the specific 
channel was calculated and removed based on ratios of voxel 
intensities between selected voxels in the unspecific recording 
and the corresponding voxels in the specific recording.  A ratio 
was computed for 40 sets of voxels selected based on the 
histogram of the unspecific recording. The unmixing algorithm 
was written in Matlab (Release 2012b, MathWorks, Natick, 
Massachusetts, United States) and applied as a XT-plugin in 
Imaris (Release 7.6.5, Bitplane, Zurich, Switzerland). These 
software programs were also used to generate all figures in the 
manuscript, except Supplementary Fig. 1e which was 
generated using SimpleElastix
31
. The atlas templates and 
associated ImarisXT plugins are freely available and can be 
requested by emailing the corresponding author. 
Statistical analysis. ROI based analysis of the total 
fluorescence signal presented in Fig. 3c, and c-Fos heat map 
intensities in Fig. 9c, were computed using multiple t-tests 
assuming unequal variance. Statistical significance was 
determined by correcting for multiple comparisons using a 
false discovery rate set to 5% for labelled peptides and 20% for 
c-Fos heat maps. The statistical analysis was performed using 
Graphpad Prism (Release 6, GraphPad Software, Inc., United 
States). 
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S1. Image registration 
 
 
Supplement Figure 1 I Image registration. (a) A LSFM template was constructed from a representative C57Bl/6J male mouse by 
registration of the brain to the CCFv3 atlas from AIBS. A white matter (WM) enhanced version of the LSFM template was constructed to 
increase the alignment quality. (b) Example of a brain sample to be registered to the LSFM template of the integrated brain atlas. Large 
deformations have occurred during the tissue processing prior to imaging. (c) The result of aligning the sample to the LSFM atlas. The 
registration was performed in separate parts to mitigate the large deformations. Separate affine and b-spline registration was performed for 
ten larger structures, here visualized by the overlay colours in the lower part of the figure. (d) LSFM atlas to which the brain sample was aligned. 
(e) Example of the registration performed for one of the larger structures in the alignment between the brain sample and LSFM atlas. Images 
are taken from the yellow structure shown in the lower part of (b)-(d). 
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S2. Accuracy of image registration 
 
 
Supplement Figure 2 I Accuracy of image registration. (a) The accuracy of the image registration for LSFM data was evaluated by 
manually placing 25 landmarks distributed throughout the LSFM template and comparing to corresponding landmarks placed in five brain samples 
after they had been registered to the LSFM template. Bar graph showing the mean error and standard deviation (n=5). The average error between 
the corresponding landmarks in samples and LSFM template was approximately 5 voxels corresponding to 100 μm. 
p. 22 
S3. c-Fos heat maps 
 
 
Supplement Figure 3 I c-Fos heat maps. (a) Raw LSFM image from a liraglutide injected mouse. The whole brain was stained for c-Fos prior to 
LSFM imaging. The red overlay shows the result of classifying cells positive for c-Fos. (b) c-Fos heatmap constructed from the image seen in (a). Red color 
indicates high density of c-Fos positive cells. (c) Maximum intensity projection image of average c-Fos signal from five animals injected with liraglutide. 
  
p. 23 
 
Supplementary Tables 
 
Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects 
Following Liraglutide Treatment 
 
 T1. Brain region abbreviations 
 T2. Most overlapping connectivity maps from AIBS  
  
p. 24 
T1. Brain region abbreviations 
Abbreviation Full name Abbreviation Full name 
ACB Nucleus accumbens MM Medial mammillary nucleus 
AHN Anterior hypothalamic nucleus MPT Medial pretectal area 
AOB Accessory olfactory bulb MRN Midbrain reticular nucleus 
AP Area postrema MTN Midline group of the dorsal thalamus 
ARH Arcuate hypothalamic nucleus NI Nucleus incertus 
AUDd Dorsal auditory area NLL Nucleus of the lateral lemniscus 
BLA Basolateral amygdalar nucleus NTS Nucleus of the solitary tract 
BMA Basomedial amygdalar nucleus OV Vascular organ of the lamina terminalis 
BST Bed nuclei of the stria terminalis PAG Periaqueductal gray 
CA1 Field CA1 PB Parabrachial nucleus 
CA2 Field CA2 PCG Pontine central gray 
CA3 Field CA3 PG Pontine gray 
CEA Central amygdalar nucleus PH Posterior hypothalamic nucleus 
COA Cortical amygdalar area PSTN Parasubthalamic nucleus 
CU Cuneate nucleus PVH Paraventricular hypothalamic nucleus 
DG Dentate gyrus PVp Periventricular hypothalamic nucleus, posterior part 
DMH Dorsomedial nucleus of the hypothalamus PVT Paraventricular nucleus of the thalamus 
DMX Dorsal motor nucleus of the vagus nerve RE Nucleus of reunions 
DR Dorsal nucleus raphe RHP Retrohippocampal region 
ECT Ectorhinal area SCH Suprachiasmatic nucleus 
ECU External cuneate nucleus SCm Superior colliculus, motor related 
GENd Geniculate group, dorsal thalamus SF Septofimbrial nucleus 
GR Gracile nucleus SFO Subfornical organ 
IC Inferior colliculus SNc Substantia nigra, compact part 
LC Locus ceruleus SNr Substantia nigra, reticular part 
LH Lateral habenula SO Supraoptic nucleus 
LHA Lateral hypothalamic area TTd Taenia tecta, dorsal part 
LPO Lateral preoptic area TU Tuberal nucleus 
LRNm Lateral reticular nucleus, magnocellular part V4 fourth ventricle 
LS Lateral septal nucleus VL lateral ventricle 
ME Median eminence VMH Ventromedial hypothalamic nucleus 
MEA Medial amygdalar nucleus VTA Ventral tegmental area 
MEPO Median preoptic nucleus ZI Zona incerta 
MH Medial habenula   
 
Supplementary Table 1 I Brain region abbreviations. Full name of brain region abbreviations used in this manuscript. Brain region names 
follow the nomenclature of the AIBS CCFv3 atlas. 
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T2. Most overlapping connectivity maps from AIBS 
Rank Structure Mouse line Experiment id 
1 NTS/DMX Rasgrf2-T2A-dCre 310853453 
2 CEA C57BL/6J 112459547 
3 PB Calb2-IRES-Cre 183284388 
4 PB Slc17a6-IRES-Cre 305404551 
5 GR/NTS Gal-Cre_KI87 175816975 
6 PB Npr3-IRES2-Cre 545427588 
7 PAG Gad2-IRES-Cre 302053755 
8 PB Chat-IRES-Cre-neo 264565965 
9 GR/NTS C57BL/6J 159648854 
10 AHN Slc18a2-Cre_OZ14 301673462 
11 PVT Ntrk1-IRES-Cre 263106751 
12 PB Chat-IRES-Cre-neo 183901489 
13 NTS/DMX Pnmt-Cre 155735108 
14 VMH/TU C57BL/6J 112228391 
15 CEA Prkcd-GluCla-CFP-IRES-Cre 265945645 
16 PVH Tac1-IRES2-Cre 300888673 
17 MEA C57BL/6J 157550122 
18 BST Ppp1r17-Cre_NL146 267764292 
19 NTS/DMX Ppp1r17-Cre_NL146 268323342 
20 NTS/DMX Tac1-IRES2-Cre 180525136 
21 DMH Sim1-Cre 159222295 
22 PVT C57BL/6J 120875111 
23 VMH/LHA Erbb4-T2A-CreERT2 277854916 
24 MEA Adcyap1-2A-Cre 272819994 
25 BLA/MEA Crh-IRES-Cre_BL 277856332 
26 AHN/LHA Nos1-CreERT2 304998039 
27 PVT Grm2-Cre_MR90 183225830 
28 CEA/MEA Crh-IRES-Cre_ZJH 267152406 
29 ARH Pomc-Cre_BL 263369222 
30 RE/PVH Rasgrf2-T2A-dCre 310976160 
 
Supplementary Table 2 I Most overlapping connectivity maps from AIBS. (a) List of the 30 most overlapping connectivity maps from 
AIBS compared to the liraglutide specific c-Fos increase following acute administration. The “Structure” column indicates the primary injection site where 
the virus used to trace the connections were injected. The “Mouse line” column indicates the mouse line used for the specific tracing experiment. The 
“Experiment id” column shows a unique AIBS id number for each experiment. All connectivity maps6 were downloaded from the AIBS data portal. 
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Glucagon-like peptide-1 (GLP-1) is a physiological regulator of appetite and long-acting GLP-1 receptor agonists (GLP-
1RA) lower food intake and bodyweight in both human and animal studies. The effects are mediated through brain 
GLP-1Rs, and several brain nuclei expressing the GLP-1R may be involved. To date, mapping the complete location of 
GLP-1R protein in the brain has been challenged by lack of good antibodies and the discrepancy between mRNA and 
protein especially relevant in neuronal axonal processes. Here, we present a novel and specific monoclonal GLP-1R 
antibody for immunohistochemistry with murine tissue and show detailed distribution of GLP-1R expression as well as 
mapping of GLP-1R mRNA by non-radioactive in situ hybridization. Semi-automated image analysis was performed to 
map the GLP-1R distribution to atlas plates from the Allen Institute of Brain Science (AIBS). The GLP-1R was 
abundantly expressed in numerous regions including the septal nucleus, the hypothalamus and the brain stem. GLP-
1R protein expression was also observed on neuronal projections in brain regions devoid of any mRNA which has not 
been observed in earlier reports. Taken together, these findings provide new knowledge on GLP-1R expression in 
neuronal cell bodies and neuronal projections. 
 
 
 
 
  
GLP-1 is a neurotransmitter produced in the brain stem, and an incretin hormone released from gut endocrine L-cells. 
GLP-1 was shown to have a role in central regulating of feeding in rats and in humans GLP-1 activated brain areas 
known to regulate food intake. (1). GLP-1 also has an important role in regulating insulin release through activation of 
the GLP-1R expressed on pancreatic beta cells thereby lowering blood glucose levels (2). The GLP-1R is a Gs protein–
coupled receptor (GPCR) (3), and mRNA coding for the receptor is widely expressed in both rodents (4) and humans 
(5). Longer acting GLP-1RAs lower overall appetite (6) and bodyweight (7) through mechanisms in the brain (8, 9). In 
rodent models, GLP-1RAs also affect other central functions such as neuroprotection, learning and memory and has 
been shown to relieve symptoms in Alzheimer and Parkinson’s disease models (10). A complete characterization of 
the localization of GLP-1Rs throughout the brain will aid to delineate GLP-1R signaling in the brain potentially involved 
in these functions. Although extensive mapping of the receptor mRNA has previously been conducted (11), the 
mapping of GLP-1R protein distribution by immunohistochemistry (IHC) has been challenged by the lack of specific 
GLP-1R antibodies (12). Recently, the GLP-1R distribution in the brain was characterized by use of GLP-1R reporter 
mice (13). Albeit extensive, potential overestimation was emphasized due to the nature of the transgene being 
expressed at any time in development. Using the primate specific GLP-1R monoclonal antibody (MAb 3F52) (14) we 
have previously described the GLP-1R distribution in the non-human primate brain (15). Here, we present an 
additional specific monoclonal GLP-1R antibody (MAb 7F38A2) for the use with murine tissue and show the detailed 
distribution of GLP-1R immunoreactivity in combination with a mapping of GLP-1R mRNA by non-radioactive in situ 
hybridization (ISH). Both antibodies have been made available through the Developmental Studies Hybridoma Bank 
(Department of Biology, University of Iowa, Iowa City, IA).The GLP-1R distribution was mapped by image 
segmentation following semi-automatic registration of the scanned histological slides to digital atlas plates from the 
AIBS mouse brain reference model (16, 17). IHC was performed on brain tissue derived from mice with a complete 
knock out of the GLP-1R (Glp-1r
-/-
) to further validate the antibody. 
 
Materials and Methods: 
Generation of anti-mouse GLP-1 receptor antibody 
   GLP-1R monoclonal antibody (7F38A2 3,6mg/ml) was generated at Novo Nordisk A/S. Glp-1r
-/-
 mice were immunized 
with baby hamster kidney (BHK) cells stably transfected with the mouse GLP-1R and antibodies were generated using 
standard hybridoma technology. The Glp-1r
-/-
 mice were on a C57BL background and were derived from the previously 
described Glp-1r
-/-
 strain (18) custom bred by Novo Nordisk A/S at Taconic. The strain is not commercially available. 
GLP-1R specific antibodies were identified by image based screening (ImageXpress, Molecular Devices, CA) using the 
BHK-mouse GLP-1R (mGLP-1R) cells used for immunization and a mock transfected BHK cell-line for counter screen. 
Following isolation of the 7F38A2 clone and purification of the antibody, binding to mGLP-1R was validated in a flow 
cytometry experiment using transiently transfected HEK-mGLP-1R and HEK mock cells. Detection was done using an 
allophycocyanin-labelled anti-mouse antibody (#115-136-071, Jackson Immunoresearch, PA) diluted 1:500. The 
7F38A2 antibody is a mouse IgG2aκ and anti-TNP is an isotype control. For the immunostaining experiments the 
antibody was biotinylated using NHS-biotin (#H1759, Sigma) following the manufacturer’s instructions. 
The antibody is now available at http://dshb.biology.uiowa.edu/Mab-7F38?sc=9&category=-109 
  
Animals 
   Male mice (C57BL/6J, and Glp1r
-/-
) and rats (Sprague Dawley) were obtained from Taconic, Denmark and housed 5 
per cage in standard, temperature controlled conditions with a 12-hour light/dark cycle. The animals had ad libitum 
access to water and regular chow (no. 1324, Altromin, Brogaarden) unless otherwise stated. Handling and housing of 
the animals were conducted in accordance with approved national regulations in Denmark which are fully compliant 
with internationally accepted principles for the care and use of laboratory animals, and with animal experimental 
licenses granted by the Danish Ministry of Justice.   
Tissue preparation and sectioning 
   The animals were anesthetized with isoflurane and transcardially perfused with heparinized (10U/ml) saline (10 ml) 
followed by 10 % neutral buffered formalin (NBF) (10 ml). Brains were removed, immersed into 10 % NBF and stored 
at room temperature for 24 hours before being embedded into paraffin.  For whole brain receptor mapping one male 
mouse was used, and the entire brain was sectioned at 4.5 µm intervals and all sections were collected. Additionally, 
two male mice (one C57BL/6J, one Glp-1r-/-) and one male rat (Sprague Dawley) were used for a follow up study. 
Section thickness was 4.5 µm. 
Immunohistochemistry  
   For whole brain receptor mapping every 20
th
 section was used for IHC. Paraffin sections were dewaxed and 
rehydrated in double distilled water. Sections were treated with 0.1 % pronase in PBS at 37°C for 10 minutes and 
rinsed in Tris-buffered saline (TBS). Sections were then treated with 1 % H2O2 in TBS for 15 minutes, washed in TBS 
with 0.05 % Tween (TBS-T), blocked with avidin for 10 minutes (Dako, Glostrup, Denmark), washed with TBS-T, 
blocked with biotin for 10 minutes (Dako, Glostrup, Denmark), washed with TBS-T, and pre-incubated with 3.2 mg/mL 
Poly L-Lysine, 3 % BSA bovine serum albumin, 7 % donkey serum and 3 % skimmed milk (Dako, Glostrup, Denmark) for 
30 minutes. Sections were incubated overnight with primary biotinylated mouse GLP-1R antibody (MAb 7F38A2, Novo 
Nordisk, Måløv, Denmark) then washed three times for 10 minutes each in TBS-T, followed by treatment with 
Vectastain ABComplexHRP in TBS for 30 minutes and washed again three times for 10 minutes each. Sections were 
developed with diaminobenzidine (DAB
+
) (Dako, Glostrup, Denmark) and counterstained with hematoxylin, rinsed in 
water, dehydrated and mounted. Sections for the follow up study were stained with similar protocol with the 
exception of an additional Tyramide Signal Amplification (TSA) step and treatment with Vectastain ABComplexHRP, 
following primary antibody incubation which this time was reduced to two hours. All images were obtained using 
Hamamatsu NanoZoomer-XR. In addition, the staining protocol has been optimized for automatic staining applying 
the Ventana Discovery Ultra staining module. For details on this protocol please refer to the supplementary material. 
In situ hybridization  
   ISH was performed using the RNAscope platform (19, 20) on neighboring sections to the sections used for whole 
brain IHC mapping. The staining was performed using a Ventana Discovery XT system (Ventana MedicalSystems, Inc., 
Tucson, AZ) with RNAscope VS FFPE RED reagent kit (cat# 320610 from Advanced Cell Diagnostics, Hayward, CA). 
Briefly, the VS RNAscope protocol was used with the following pretreatment conditions: boiling for 2 minutes and 
pretreatment 2+3 steps for 4 minutes each with probes for bacterial DapB (negative control, cat. no. 310048), and 
mouse GLP-1R (cat. no. 415896). Images were obtained using Hamamatsu NanoZoomer-XR. 
To validate the signal obtained for GLP-1R mRNA, another mouse GLP-1R probe (no. 415906) non-overlapping in 
sequence with probe no. 415896 was used on adjacent sagittal mouse brain sections. The signals obtained with both 
probes showed a complete overlap (data not shown). 
  
Image analysis and atlas plate generation 
   Image segmentation of the IHC and ISH slide scanner images were performed using a multinomial regression 
classifier trained on a constructed mosaic image for each staining type. The r,g,b values of the images were used as 
input features.  Prior to segmentation each IHC/ISH image pair was registered to a digital atlas plate obtained from the 
AIBS mouse brain reference model (16, 17). The specific atlas plates were manually selected from a collection of 528 
plates. The image registration was performed in a coarse to fine manner with an affine transformation followed by 
non-linear b-spline transformation using sum of squared difference as similarity measure. All registrations were 
computed using Elastix (21). The final atlas plates were constructed by summing segmented signal inside a square 
mask moving across the registered images. A blue circle (IHC) or a red square (ISH) was drawn on the atlas plate if 
positive signal was detected. The diameter of the marker was based on the signal count applying a logarithmic scale to 
show both weak and strong signals. Following the automatic atlas plate generation manual corrections were 
performed in regions where the automatic image registration was not sufficiently accurate. 
 
 
Table 1. Antibodies used 
Peptide/Protein 
Target 
Manufacturer, Catalog #, 
and/or Name of 
Individual 
Providing the Antibody 
Species Raised in; 
Monoclonal or 
Polyclonal 
Dilution 
Used 
RRID 
GLP-1R Developmental Studies 
Hybridoma Bank, Mab 
7F38 
Mouse, Monoclonal 1:720 AB_2618101 
 
Results 
Antibody specificity 
   IHC staining with the GLP-1R antibody revealed high intensity staining with good resolution and low background 
(Figure 1). The antibody was specific for GLP-1Rs expressed in peripheral organs such as the Brunner’s gland (Figure 1, 
A-B) and further for mouse (Figure 1, C-F) and rat (Figure 1, G-H) brain. The expressional profile of GLP-1R was 
evaluated throughout the entire mouse brain, and this expression was confirmed in select regions in the rat brain in 
hypothalamus and brain stem showing correspondence between the two species in the regions investigated. 
However, some discrepancies existed between mouse and rat where GLP-1R expression could be observed in mouse 
lateral habenula, nucleus accumbens and in the nucleus of the lateral olfactory tract/cortical amygdalar area which 
was absent in rat brain (data not shown). Validation of the antibody has further been performed for GLP-1Rs in 
pancreas (22), kidney (23) and other peripheral GLP-1R expressing organs such as GI tract, lung and thyroid (data not 
shown).  
 Figure 1. GLP-1R IHC with antibody Mab 7F38A2 on paraffin-embedded mouse Brunner’s Gland (A–B) and mouse brain (C-F). B, 
High magnification of the solid-line box in A. E and F, Magnifications of solid-line boxed areas in C and D, respectively. C and E are 
from a Glp-1r
-/-
 mouse while D and F are from a C57BL/6J mouse. GLP-1R IHC with antibody Mab 7F38A2 on paraffin-embedded rat 
brain (G–H). G, High magnification image of the hypothalamus showing positive staining in arcuate hypothalamic nucleus and 
median eminence. H, High magnification image showing positive staining in area postrema, dorsal motor nucleus of the vagus 
nerve and nucleus of the solitary tract. Scale bar in A corresponds to 2000 um. Scale bar in B corresponds to 100 um. Scale bar in C-
D corresponds to 2000 um. Scale bar in E-F corresponds to 250 um. Scale bar in G corresponds to 500 um. Scale bar in H 
corresponds to 500 um. 
Distribution of GLP-1R  
Overall, GLP-1R protein and mRNA co-localized in most regions, however, some discrepancies was found such as in 
the posterior hippocampus, median eminence and terminal field of accessory olfactory bulb projections. The findings 
are summarized in Table 2 and on the atlas plate overlays (Figure 2). 
Telencephalon. In agreement with previous reports, GLP-1R protein positive cells were identified in the olfactory bulb, 
amygdala, dentate gyrus, septal nucleus, preoptic area, septofimbrial nucleus,  triangular nucleus of septum, tenia 
tecta, vascular organ of the laminae terminalis, nucleus accumbens and bed nucleus of stria terminalis. Furthermore, 
protein was observed in the subfornical organ and in the terminal field of accessory olfactory bulb projections (the 
latter is included in the cortical amygdalar area in Table 2) where mRNA expression was absent (Table 2). Especially in 
those regions where protein expression differed from mRNA expression, the specificity of the antibody was further 
validated by antibody staining on brain sections from Glp-1r 
-/-
 mice. The data from the Glp-1r
-/- 
mice showed complete 
absence of GLP-1R immunoreactivity, further establishing this antibody as specific towards the GLP-1R and confirming 
the presence of GLP-1R protein in these regions (Figure 3). 
Diencephalon. In the diencephalon GLP-1R protein and mRNA was observed in cells in zona incerta, tuberal nucleus, 
peripeduncular nucleus, and in hypothalamus in the arcuate nucleus, dorsomedial hypothalamic nucleus, lateral 
hypothalamic nucleus, paraventricular hypothalamic nucleus and supraoptic nucleus. Furthermore, GLP-1R protein 
was observed in median eminence as fibers only with no mRNA expression. The same pattern of presence of GLP-1R 
protein in the absence of mRNA expression was observed in the geniculate group of thalamus, posterior hypothalamic 
nucleus, habenula, and retrochiasmatic area (Table 2). When comparing mRNA expression reported by AIBS 
(http://www.brain-map.org/) with data obtained in the present study several areas expressing GLP-1R mRNA in the 
AIBS atlas were negative in the present study (Table 2). 
Mesencephalon. GLP-1R was observed in the anterior pretectal nucleus, medial and posterior pretectal area, the 
periaqueductal gray, and in the substantia nigra. GLP-1R protein was also observed in the motor related part of 
superior colliculus whereas mRNA expression could be observed in both the motor related and the sensory related 
part of superior colliculus. Further discrepancies were observed in the dorsal raphe, the medial mammillary nucleus, 
the midbrain reticular nucleus and the ventral spinocerebellar tract where receptor was observed as protein on fibers 
only, lacking mRNA expression.   
Pons. In pons, GLP-1R protein and mRNA expression could be observed in the pontine grey, the parabrachial nucleus 
and the principal sensory nucleus of the trigeminal. Very few brain regions were positive for both protein and mRNA 
and only protein was observed in the nucleus incertus, nucleus of the lateral lemniscus, and the superior olivary 
complex whereas only mRNA was observed in the pontine reticular nucleus. 
Medulla. In Medulla, GLP-1R was observed in the area postrema, cuneate nucleus, inferior olivary complex, lateral 
reticular nucleus, nucleus tractus solitarus, medial vestibular nucleus, and the spinal nucleus of the trigeminal. GLP-1R 
protein but not mRNA was observed in the dorsal motor nucleus of the vagus nerve and in flocculus, residing in 
cerebellum, whereas mRNA was evident in nucleus ambiguus, and in the reticular nucleus. 
 
 
 Figure 2. Atlas plates showing distribution of signals for mouse GLP-1R ISH (red squares) and GLP-1R IHC (blue circles). The 
distribution is overlaid onto digital atlas plates constructed from the AIBS mouse brain atlas. The distribution of GLP-1R mRNA and 
protein are indicated on the left half of the atlas plates and brain regions with positive staining for either GLP-1R mRNA or protein 
are highlighted with a solid color on the right half of the atlas plates.  Brain region abbreviations follow the nomenclature of the 
AIBS mouse brain reference atlas which can be found at: http://atlas.brain-map.org/ 
  
 Figure 2 (continued). Atlas plates showing distribution of signals for mouse GLP-1R ISH (red squares) and GLP-1R IHC (blue 
circles). The distribution is overlaid onto digital atlas plates constructed from the AIBS mouse brain atlas. The distribution of GLP-1R 
mRNA and protein are indicated on the left half of the atlas plates and brain regions with positive staining for either GLP-1R mRNA 
or protein are highlighted with a solid color on the right half of the atlas plates.  Brain region abbreviations follow the nomenclature 
of the AIBS mouse brain reference atlas which can be found at: http://atlas.brain-map.org/ 
Table 2. Summary of GLP-1R (IHC and ISH) location in C57BL/6J mouse brain and comparison to external references 
 
Structure Area Protein mRNA 
Cork et al 
(13) (protein) 
AIBS (mRNA) 
Telencephalon AOB Accessory olfactory bulb + + + + 
BMA Basomedial amygdalar nucleus + - + + 
CeA Central amygdala + + + + 
CeA/AAA Central amygdala/Anterior 
amygdalar area 
+ + + + 
COA Cortical amygdalar area + - + + 
DG Dentate gurys + + + + 
LPO Lateral preoptic area + + + + 
LS Lateral septal nucleus + + + + 
NLOT/COA Nucleus of the lateral olfactory 
tract/Cortical amygdalar area 
+ - + + 
PA Posterior amygdalar nucleus + - + + 
SF Septofimbrial nucleus + + NA + 
SFO Subfornical organ + + + + 
TRS Triangular nucleus of septum - + NA + 
TT Tenia tecta + + + + 
OV Vascular organ of the laminae 
terminalis 
+ NA + NA 
ACB Nucleus accumbens + + + + 
BST Bed nucleus of stria terminalis + + + + 
Diencephalon ARH Arcuate hypothalamic nucleus + + + + 
DMH Dorsomedial hypothalamic 
nucleus 
+ + + + 
GENd Geniculate group, dorsal 
thalamus 
+ - + + 
Hb Habenula  + - + + 
LHA Lateral hypothalamic nucleus + + + + 
ME Median eminence + - NA + 
PH Posterior hypothalamic 
nucleus 
+ - + + 
PP Peripeduncular nucleus + + NA + 
PVH Paraventricular hypothalamic 
nucleus 
+ + + + 
RCH Retrochiasmatic area + - + + 
SO Supraoptic nucleus + + NA + 
TU Tuberal nucleus + + NA + 
ZI Zona incerta + + + + 
Mesencephalon APN Anterior pretectal nucleus + + + + 
DR Dorsal raphe + - NA + 
MM Medial mammillary nucleus + - + + 
MPT Medial pretectal area + + + + 
MRN Midbrain reticular nucleus + - NA + 
PAG Periaqueductal gray + + + + 
PPT Posterior pretectal area + + + + 
SCs Superior colliculus, sensory 
related 
- + NA + 
SCm Superior colliculus, motor 
related 
+ + NA + 
SCTV ventral spinocerebellar tract + - NA + 
SNr Substantia nigra, reticular part + + NA + 
SNc Substantia nigra, compact part + + NA + 
Pons NI Nucleus incertus + - NA + 
NLL Nucleus of the lateral 
lemniscus 
+ - NA + 
PB Parabrachial nucleus + + NA + 
PCG Pontine central gray + - NA + 
PG Pontine gray + + NA + 
PRNc Pontine reticular nucleus, 
caudal part 
- + NA + 
PRNr Pontine reticular nucleus - + NA + 
PSV Principal sensory nucleus of 
the trigeminal 
+ + NA + 
SOC Superior olivary complex + - NA + 
Medulla AMB Nucleus ambiguus - + NA + 
AP Area postrema + + + + 
CU Cuneate nucleus + + NA + 
DMX Dorsal motor nucleus of the 
vagus nerve 
+ - NA + 
ECU External cuneate nucleus + + NA + 
FL  Flocculus (cerebellum) + - NA + 
IO Inferior olivary complex + + + + 
LRNm Lateral reticular nucleus, 
magnocellular part 
+ + NA + 
MARN Magnocellular reticular 
nucleus 
- + NA + 
MDRN Medullary reticular nucleus - + NA + 
MV Medial vestibular nucleus + + NA + 
NTS Nucleus tractus solitarus + + + + 
PARN Parvicellular reticular nucleus - + NA + 
SPVC Spinal nucleus of the 
trigeminal, caudal part 
+ + NA + 
Presence (+) or absence (-) of GLP-1R protein and mRNA in mouse brain. The two right columns indicate whether GLP-1R was 
observed as protein (Cork et al) or mRNA (AIBS). NA: not assessed/reported. 
 
 
 
Figure 3. High magnification images of adjacent sections of C57BL/6J mouse brain tissue focusing on terminal field of accessory 
olfactory bulb projections (A-B). A, Mouse GLP-1R ISH showing lack of signal. B, GLP-1R IHC with antibody Mab 7F38A2 showing 
positive staining. C, GLP-1R IHC with antibody Mab 7F38A2 on a corresponding section from a Glp1r
-/- 
mouse brain showing 
negative staining. Scale bars correspond to 400 um. 
Discussion 
The reliable detection of the GLP-1R expression in tissues using IHC has been hampered by a lack of specific antibodies 
thus limiting well validated histological mapping studies to the detection of GLP-1R mRNA using ISH (12, 24, 25) and 
protein using in situ ligand binding with low spatial resolution (26). In this study an extensive mapping of GLP-1R 
mRNA and protein expression in the mouse brain is reported. For localization of GLP-1R protein a monoclonal GLP-1R 
antibody was used which is highly specific for murine GLP-1R as demonstrated by the complete absence of reactivity 
in mice lacking the GLP-1R. The localization of GLP-1R protein was combined with detection of GLP-1R mRNA on 
adjacent sections using non-radioactive ISH, enabling a higher accuracy for anatomical localization compared to a 
radioactivity based approach. The expression patterns observed showed good alignment between protein and mRNA 
expression but also revealed some regions only positive for GLP-1R protein and encompassing axonal projections. This 
is a well described phenomenon in the brain where protein and gene expression do not always correlate (27, 28, 29), 
possibly in situations where protein can be transported away from the nuclear processing site along the axonal 
processes. This phenomenon necessitates caution when interpreting potential GLP-1 interacting brain regions and 
neurons based on receptor mRNA expression alone, as such data will underestimate the number of GLP-1 binding 
sites. The distribution of GLP-1R protein in the mouse brain has previously been described using a transgene Glp-1r 
reporter mouse (13). When comparing GLP-1R protein expression detected using the antibody in the present study 
with the study by Cork et al (13) there is a high level of agreement with a few exceptions where some positive regions 
were seen using IHC but not reported by Cork et al. Of note, several of these regions were regions lacking mRNA 
expression, indicating the presence of protein exclusively on projections and terminals. Thus, compared to the 
transgene Glp-1r reporter mouse model, antibody detection with IHC represents a superior method to visualize axonal 
projection throughout the brain. Interestingly, the concern for artefactual overexpression of GLP-1R in the Glp-1r 
reporter mouse as a result of accumulated gene transcription during embryogenesis does not seem to be a problem in 
the case of the GLP-1R, as all regions reported positive in the reporter mouse were also seen with antibody staining.  
Comparing mRNA expression in the present study to that reported by AIBS revealed several areas where mRNA was 
reported to be present by AIBS (e.g. nucleus of the trapezoid body, septohippocampal nucleus, dorsal peduncular 
area, and tegmental reticular nucleus) but not observed in our study (and hence not included in Table 2). These 
inconsistencies are likely due to a higher specificity of the RNAscope ISH platform used here as demonstrated by the 
full overlap of signals obtained with two non-overlapping probes for GLP-1R. Another explanation could be the more 
extensive sampling of the mouse brain in studies reported by AIBS potentially revealing sub nuclei with limited GLP-1R 
expression that was not picked up in this study. 
To verify that the antibody could also be applied to rat tissue, select sections from rat brain were stained and 
examined. Although there was a good agreement with respect to localization of the GLP-1R between mouse and rat 
on sections with hypothalamus and brain stem, it must be emphasized that the entire rat brain was not analyzed and 
a discrepancy between mouse and rat in GLP-1R localization in the brain was detected in some regions. In general 
more GLP-1R protein was observed in the mouse brain compared to the rat brain. A large part of the additional GLP-
1R protein was seen in mouse axonal processes such as in medial habenula and cortical amygdalar area which were 
absent in the rat. Thus, to fully characterize the GLP-1R in rat brain a full mapping is needed rather than assuming 
complete correspondence between species. 
Considering the relative small fraction of neurons in the hindbrain that produce GLP-1, a remarkable abundance of 
GLP-1Rs were found to be expressed throughout the brain indicating potential diverse actions of this 
neurotransmitter. Indeed, central GLP-1 activity has been reported to affect functions such as feeding behavior, body 
weight and temperature, malaise, fluid homeostasis, stress response, and learning and memory (30, 31). One of the 
most abundant GLP-1R populations was found in the caudal division of the lateral septal nucleus a population that is 
little understood with respect to GLP-1 actions. The caudal part of lateral septal nucleus has been characterized as 
abundant in somatostatin neurons which has been shown to act inhibitory in septal nucleus (32, 33). Further building 
on this inhibitory mechanism, other studies have suggested that GLP-1R expressing neurons in LS are GABA’ergic and 
connected to GLP-1 actions on behaviors associated with reward (34, 35). Septal projections are extensive and include 
innervation of hypothalamus, supramammilary nucleus, hippocampus, thalamus, and ventral tegmental area (36). 
Thus the involvement in reward signaling may only be a one GLP-1 mediated behavior initialized from this area.  
Another area with high expression of GLP-1R positive fibers was in the dentate gyrus which is the principal input to the 
rest of the hippocampus forming the “tri-synaptic hippocampal circuit” associated with episodic memory 
consolidation and formation (37). The dentate gyrus is capable of generating new granule cells in the adult brain (38, 
39), which has been linked to memory formation and maintenance as well as neuroprotection (40, 41). Hence, GLP-1R 
expression in this area could be coupled to some of the beneficial effects reported with GLP-1 regulation of memory 
and Alzheimer’s disease (42) and neuroprotection (31). 
A high expression of GLP-1R was also identified on fibers projecting to the median eminence. The median eminence is 
usually associated with the integration of the hypothalamic pituitary axis serving as an area of release from 
paraventricular hypothalamic neurons to the bloodstream. On top of this, literature suggests the median eminence to 
be a site for uptake of peripheral peptides such as leptin and ghrelin from the blood (43, 44) through receptor specific 
uptake; this could be extended to include GLP-1RAs. Indeed all circumventricular organs including the median 
eminence have a high expression of GLP-1R suggesting interaction with peripheral GLP-1 in these regions.  
In summary, we report here a full mapping of GLP-1R protein and mRNA in the mouse brain using IHC with a specific 
monoclonal antibody and ISH, respectively. The strength of using a fully validated and specific antibody is emphasized 
by the ability to detect GLP-1R protein in regions devoid of mRNA and in neuronal projections where it was not 
observed using a transgenic reporter system.  
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Supplementary material – Automated (Ventana) protocol for IHC detection with MAb clone 7F38 
 
Name Code no. Firma 
Reaction buffer 05353955001 Roche 
Discovery wash 07311079001 Roche 
LCS ultra 05424534001 Roche 
Discovery Inhibitor 760-4840 Roche 
Discovery CC1 950-224 Roche 
Protease 3 760-2020 Roche 
Rb-Glp1r-7f38 0180-0000-0233-1B Novo Nordisk A/S 
Chromogene Purple 760-229 Roche 
Hematoxylin 790-2208 Roche 
Blueing reagent 760-2037 Roche 
Rb-HQ 760-4818 Roche 
Cromomap DAB 760-159 Roche 
a-HQ_HRP 760-4820 Roche 
TNB(blocking reagent) FP1012 Perkin Elmer 
TBS-buffer 10X pH 7,4 AMPQ40829.5000 Ampliqon 
 
Deparaffinization 70°C, 3 cycles of 8 min each. 
Pretreatment, enzyme, Protease 3 at 37°C for 16min. 
Inhibitor, Discovery Inhibitor for 12 min. 
Antibodyblocking, 0,5% TNB for 28 min. 
Antibody, GLP1R 7F38 1µg/ml in TBS-buffer at 37°C for 60min. 
Linking Antibody (2.nd ab) , Anti-RabbitHQ, at 37°C for 24min. 
Enzyme Conjugate, Anti-HQ HRP, 16 min. 
DAB, time pre-set by roche-not adjustible. 
Counterstain, Hematoxylin II, for 8 min. 
Bluing reagent, for 4 min. 
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Abstract. With the recent advance in 3D microscopy such as Single
Plane Illumination Microscopy (SPIM) it is possible to obtain high res-
olution image volumes of the entire mouse brain. These data can be
used to study the access of several peptides such as the glucagon-like
peptide-1 (GLP-1) analogue Exendin-4, into the brain with the aim of
developing medication for obesity. To investigate mode of action of the
medication it is important to identify the specific anatomical brain nuclei
that are targeted by the compound. Such segmentations can be obtained
using an annotated digital brain atlas. We construct a SPIM brain atlas
based on the Allen mouse brain 3D reference model and use it to analyze
the access of peripherally injected Exendin-4 into the brain compared to
a negative control group. The constructed atlas consists of an average
SPIM volume obtained from eight C57BL mouse brains using group-wise
registration. A cross-modality registration is performed between the con-
structed average volume and the Allen mouse brain reference model to
allow propagation of annotations to the SPIM average brain. Finally,
manual corrections of the annotations are performed and validated by
visual inspection. The study shows that Exendin-4 have access to brain
regions such as the arcuate hypothalamic nucleus and the nucleus of the
solitary tract, which are areas involved in regulating food intake.
Keywords: Mouse brain ·Allen mouse brain 3D reference model ·Digital
atlas ·Atlas segmentation ·Image registration
1 Introduction
Obesity is a disease, which has become a worldwide epidemic growing at an
alarming rate. For the individual the consequence of obesity is an increased risk
of acquiring metabolic disorders like type 2 diabetes and cardiovascular diseases.
Glucagon-like peptide-1 (GLP-1) analogues such as Exendin-4 have shown a pos-
itive effect on weight loss and thus belongs to a class of peptides which might
be used for tomorrow’s obesity medication. A way to study the distribution of
GLP-1 analogues in the brain after administration is using histology, [3]. Due to
the numerous histological slides that need to be produced, these types of studies
are expensive and time consuming. Additionally, it is difficult to compare results
across studies due to the difficulty of precisely denoting anatomical structures
in the data.
One technique that might overcome these limitations is the new imaging modal-
ity Single Plane Illumination Microscopy (SPIM), which is a non-destructive
method to produce well-registered optical sections suitable for 3D reconstruc-
tion [7]. SPIM is a type of fluorescence microscopy with the ability to produce
3D data of macroscopic objects in cellular resolution, e.g. of the mouse brain [5].
A popular segmentation strategy in neuro-imaging is the use of computational
atlases, used in various imaging modalities both in human and animal models
[4]. An atlas typically consists of a reference volume with accompanied anno-
tations. The reference volume can be produced by computation of averages of
ensembles of segmented images after image registration, [2]. A new image can
then be segmented by image registration to the atlas volume and superimposi-
tion of the segmented structures from the atlas. For common imaging modalities
some computational atlases of the mouse brain are available, e.g. [6], [9]. To the
authors’ knowledge no SPIM brain atlases have been published.
We construct a SPIM atlas by group-wise registration of recorded mouse brains.
A good initial guess of the annotations are obtained by cross-modality regis-
tration to an existing atlas, and finally manual corrections are performed to
complete the atlas. The Allen mouse brain reference model, [9], is used as the
source of the annotations due to the model’s high quality and detailed annota-
tions.
We use the constructed atlas to investigate the access of peripherally injected
Exendin-4 into the C57BL mouse brain based on quantification inside the seg-
mented brain structures.
2 Method
2.1 Allen mouse brain reference model
A 3-D reference model, [9], is available for download using the API of the Allen
Brain Atlas Data Portal [1]. The model is based on 132 annotated coronal plates
of the adult mouse brain. Annotations are transferred from this reference model
onto the constructed SPIM brain atlas.
Reference volume. The Allen 3-D brain volume was reconstructed from anno-
tated plates using a combination of high frequency section-to-section histology
registration with low-frequency histology to (ex-cranio) MRI registration. The
reference volume was constructed in 2006, [15], and later updated in 2011. The
volume is based on Nissl stains that highlights brain regions of high nuclei con-
centration. The volume is available for download in 25 µm isotropic resolution.
Prior to usage a smoothing of the reference volume and removal of the outer
part of the olfactory bulb were performed.
Reference annotations. The full Allen atlas consists of 1204 symmetric 3-D
structures, which are more than needed in this study. For the study of GLP-1
analogues 56 structures were chosen, with the highest concentration of structures
in regions relevant for appetite control and obesity such as the hypothalamus.
Each structure is color-coded to visually show the hierarchical position in the
brain.
2.2 SPIM brains
In total 16 mice brains were recorded using SPIM. Eight brains were used for
atlas construction and eight brains were used to quantify the access of Exendin-4
into the brain.
Tissue preparation and data recording. The conditions of housing and care
of the animals as well as performance of the experiments are in agreement with
the Danish law of animal experimentation. After sedation the mice were eutha-
nized by cardiac perfusion with heparinized saline followed by neutral buffered
formalin. The brains were removed and cleared for SPIM by a stepwise dehydra-
tion and clearing process using tetra hydro-flurane and di-benzyl-ether (DBE),
respectively.
Data were recorded with a dual side illumination Lavision system utilizing a
SuperK white light laser, a 620-nm emission filter, a 700-nm excitation filter,
an Olympus microscope, and an Andor Neo sCMOS camera. The brain samples
were immersed in a DBE bath during recording to minimize the difference in
refractive index. The recordings were performed in 5.16 µm isotropic resolution.
2.3 Atlas construction
The constructed atlas contains 56 brain structures. Using the naming convention
of the Allen reference model, [9], the structures are: Isocortex, AOB, AON, MOB,
HPF, CA1, CA2, CA3, DG, BLA, ACB, CEA, CP, LSc, LSr, LSv, MS, SF, SH,
TH, PVH, PVHd, ARH, SO, Pvi, PVa, Pvpo, OV, SFO, DMH, SCH, PVp, PH,
VMH, LHA, ZI, ME, CLI, DR, IF, SNc, SNr, IPN, RL, VTA, PBl, PBm, AP,
NTS, CB, ts, VL, AQ, c, V3, and V4. Two additional annotations are included
consisting of other tissue and background, respectively.
Pre-processing. Following an initial cropping, the brain volumes were down
sampled to 15 µm isotropic resolution and the axes were reordered to match
the orientation of the Allen reference model with the first axis being dorsal-
ventral, the second axis being lateral-medial, and the third axis being rostral-
caudal. The data recording process deformed the structure of the olfactory bulb.
Therefore this structure was cropped from the data along with the medulla
oblongata, which is not part of the Allen reference model. The background voxels
were set to zero and additional zero-padding was performed to center the brain
inside the volume. Data obtained with the SPIM modality contains a bias field
due to continuos attenuation of the laser sheet by the tissue sample, as well
as a non-uniform intensity profile in the generated laser sheet depending on
the microscope construction. Bias field correction was applied using a toolbox
developed in [8]. Outliers originating from air bubbles trapped in the ventricular
system during the tissue preparation process were removed.
After the individual pre-processing of the brains, intensity normalization was
performed based on matching the median value of the brains. This was done to
avoid creating an average volume biased towards scans with higher intensities
caused by different microscope settings rather than on real biological differences.
Creation of SPIM atlas. Creation of the SPIM atlas was based on image
registration between recorded SPIM data and the Allen reference model. The
main registrations used in this work are based on a hierarchical transformation
model, introduced in [11], which captures the global and local deformations of
the tissue,
T(x, y, z) = Tglobal(x, y, z) + Tlocal(x, y, z) (1)
where the global transformation is a standard affine transformation. The local
transformation model, a Free Form Deformation (FFD), is in 3D defined by an
nx × ny × nz mesh of control points Φ with spacing (δx,δy,δz). The underlying
image is then deformed by manipulating the mesh of control points based on
B-splines.
A fast way to regularize the deformation is to apply multi-level B-splines [12];
i.e. given control point resolutions Φ1...ΦH , at levels 1, ...,H, the final local trans-
formation is the sum of the transformations at each level,
Tlocal =
H∑
h=1
Thlocal (2)
All transformations were calculated and applied using the Image Registration
Toolkit, which was used under Licence from Ixico Ltd. [11], [12], [14].
The constructed SPIM atlas, based on the eight recorded SPIM scans, was cre-
ated based on the following algorithm,
Algorithm 1 SPIM atlas construction
1: Register (rigid) all mouse brains to Allen reference model
2: Template = Intensity average of all registered mouse brains
3: Repeat
4: Register (FFD) all mouse brains to template
5: Template = Intensity average of all registered mouse brains
6: Until template stops changing
7: Register (FFD) Allen reference model (volume data + annotation data) to SPIM
template
In line 1, using normalized mutual information, all scans were linearly (3 degrees
of freedom for rotations, 3 degrees of freedom for translations) registered towards
a pre-existing atlas, namely the Allen reference model. All scans were then av-
eraged to create the first population atlas, representing the average anatomy of
the study samples. An iterative 3 generation multi scale non-linear alignment
procedure was then begun, registering each mouse towards the atlas of the pre-
vious non-linear generation using cross correlation as similarity measure. In line
6, the root-mean-square error between the voxel intensities of the current atlas
and the previous atlas was calculated and an appropriate threshold value chosen
to define the state where the atlas stopped changing. In line 7, the FFD trans-
formation was calculated again based on the volume data of the Allen reference
model. The calculated transformation was then applied to the annotation data
of the model to bring these into alignment with the SPIM atlas volume. The
last step in completing the SPIM atlas was manual correction of the computed
annotations.
2.4 Exendin-4 study
A concentration of 240 nmol/kg Exendin-4 was fluorescently labelled with VivoTag-
S 750 (Perkin Elmer) and injected into 6-8 weeks old male C57BL mice (Taconic)
two hours prior to euthanization.
A two channel SPIM scan was performed of the brains with one channel recording
the auto-fluorescence of the tissue, and the other channel recording the specific
signal of the labelled Exendin-4. Similarly, four negative control brains were
scanned following vehicle injection using the same data recording protocol. Seg-
mentations of the brains were obtained by non-linear registration to the con-
structed atlas and propagation of the annotations. Detection of signal in the
statistical analysis was performed by observing the 95th percentile inside each
segmented brain area after removal of any bleed-through signal from the auto-
fluorescence channel. The 95th percentile was used to eliminate outliers caused
by small air bubbles typically situated on the surface of the tissue.
3 Results
3.1 Overview of constructed atlas
A mid-coronal (a-b), mid-transverse (c-d), and mid-sagtial (e-f) view of the
constructed SPIM atlas is seen in Figure 1. The left column of images shows the
reference volume, and the right column shows the annotations overlaid onto the
reference volume.
Fig. 1. Overview of constructed atlas. Left column (a,c,e) shows the atlas volume and
the right column (b,d,f) shows the atlas with overlaid annotations. Green denotes
the isocortex, red colors are part of the hypothalamus and thalamus, yellow is the
cerebellum, blue structures belong to cerebral nuclei, and purple denotes midbrain
structures.
3.2 Segmentation example
An example of an automatic segmentation performed using the constructed at-
las is seen in Figure 2. The left image shows an example of an auto-fluorescence
channel recorded as part of the Exendin-4 study, and the right image shows
the corresponding specific channel overlaid with calculated annotations. Strong
signals are seen ventrally in the hypothalamic structures and caudally near the
hindbrain structures.
Fig. 2. Example of segmentation of a mouse brain following injection of fluorescent
labelled Exendin-4. (a): Auto-fluorescence channel of the recording. (b): Specific fluo-
rescence channel overlaid with calculated segmentaiton. High intensity (white) corre-
sponds to a high fluorescence signal. Green denotes the isocortex, red colors are part
of the hypothalamus and thalamus, yellow is the cerebellum, blue structures belong to
cerebral nuclei, and purple denotes midbrain structures.
3.3 Quantification results
Quantification results inside segmented brain regions for the Exendin-4 study
are seen in Figure 3. The bar height for each structure corresponds to the mean
value of the 95th percentile detected inside that structure in the four mouse
brains. The error bars show the standard deviation. Signal is detected inside
Nucleus of the solitary tract (NTS), Area postrema (AP), Median eminence
(ME), Periventricular hypothalamic nucleus - posterior part (PVp), Vascular
organ of the lamina terminalis (OV), Periventricular hypothalamic nucleus - an-
terior part (PVa), Arcuate hypothalamic nucleus (ARH), Septofimbrial nucleus
(SF), Lateral septal nucleus, caudal part (LSc). Signal is defined as a p-value
less than 0.05 when performing a two sample t-test between the Exendin-4 group
and the negative control group, with the null hypothesis of equal means in the
groups, and the alternative hypothesis being the Exendin-4 group having a larger
mean value than the negative control group. The sample size is four mice in each
group. The scale of the x-axis on the plot is in arbitrary unit.
Fig. 3. Signal detection inside the automatically segmented brain regions following
injection of Exendin-4. *p<0.05; **p<0.01; ***p<0.001 in a right tailed two sample t-
test between the Exendin-4 group and the negative control group. Colors and acronyms
follow the convention of the Allen 3D reference model.
4 Discussion
Access of Exendin-4 is seen in circumventricular structures such as ME, OV, and
AP, which are brain areas not protected by the blood-brain-barrier and there-
fore expected to show a signal if any GLP-1 receptors are present. Access is also
observed in other areas known to contain GLP-1 receptors such as the ARH and
NTS. These areas have previously been identified as being part of the complex
system that regulates food intake [13].
Observing the quantitative results in Figure 3, it is seen that some bars have a
negative value. This is not expected in a scan setup where the value zero corre-
sponds to no measured signal. The negative values appear due to the method of
subtracting bleed-through signal of the auto-fluorescence channel. In future stud-
ies this can be avoided by using a better algorithm to remove the bleed-through
signal. Although 58 t-test were made, no correction for multiple comparisons has
been applied since the nature of the study was explorative.
Due to the lack of a ground truth a measure such as the Dice score can not
be computed to evaluate the quality of the atlas, but by visually comparing the
constructed atlas to other resources such as [10] the annotations of the structures
appear to be correct. Basing a new atlas on a well established resource such as the
Allen reference model has shown to reduce the dependency on neuro-anatomical
expertise in order to construct the atlas. This is useful when working with a new
image modality such as the SPIM system, and a similar approach can also be
useful for constructing atlases for tomorrow’s imaging systems.
Required manual corrections, and the overall quality of the atlas, is heavily
influenced by the registration between the Allen reference model and the con-
structed SPIM average brain. The registration is challenging since it is both
cross-modality and cross-subject. We have obtained a satisfactory result by vary-
ing registration parameters, but improvements can be obtained by manually
adding landmarks. This could especially be useful around the ventricular system
where the largest differences are observed between the reference model and the
SPIM scans.
5 Conclusion
Access of Exendin-4 in brain structures known to regulate food intake is suc-
cessfully demonstrated. Based on visual inspection the constructed brain atlas
contains correct annotations of the included structures. Evaluating brain access
of GLP-1 analogues, such as Exendin-4, will be important to investigate mode
of action of the analogues with hope of developing future obesity medication.
Since the constructed atlas is based on the Allen mouse brain reference model
additional brain structures can easily be added if found relevant for study of
other substances than GLP-1-analogues.
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Leptin was once thought a promising treatment for obesity but failed as the weight loss experienced by lean individuals 
was not transferrable to obese individuals. Leptin resistance has since been debated in the scientific community. In this 
paper we apply 3D imaging and analysis techniques to show why exogenous leptin administration is ineffective as an 
obesity treatment. We first mapped the leptin receptor location in the full mouse brain to identify possible direct targets 
of circulating leptin. Next, a time course study was performed to learn which time points different brain regions were 
activated following a peripheral leptin dose. Most pStat3 activation peak between 60 minutes and 120 minutes after 
leptin administration. Lastly, the pStat3 response to exogenous leptin was compared in lean mice, DIO mice, and db/db 
mice. The dynamics of the pStat3 response was significantly reduced in DIO mice compared to lean mice. No response was 
seen in the db/db model. In summary, this work provides a comprehensive 3D map on the pStat3 response in both lean 
and obese mice and demonstrates that the pStat3 signalling pathway is constitutively active in the brain of obese animals. 
We speculate that the high levels of leptin in the plasma leads to constant activation of pStat3 signalling in the neurons 
responsible for controlling appetite and food intake thus preventing exogenous leptin to add any additional information.   
  
Introduction 
Over the past decades the increase in individuals with obesity has reached epidemic proportion, posing a huge challenge 
on societies and healthcare budgets [1]. For the affected individual the consequence of obesity increased risk of metabolic 
diseases like type II diabetes and cardiovascular disease [2]. The obesity prevalence is attributed to the combined impact 
of increased high-energy food consumption and decreased physical activity. Throughout evolution complex physiological 
systems have evolved to regulate energy homeostasis. Leptin, a hormone secreted by adipose tissue, and its receptor are 
an integral component of this system [3, 4]. The leptin receptor (LepRb) is abundantly expressed throughout the mouse 
brain, with the largest concentrations of LepRb positive neurons found in the hypothalamus [5]. In the hypothalamus 
leptin has been shown to activate neurons expressing pro-opiommelanocortin (POMC) and inhibit neurons that co-express 
neuropeptide Y (NPY) and agouti-related peptide (AgRP) to decrease feeding [6,7]. In the hindbrain Leptin has been shown 
to act synergistically with the vagal actions of gut released anorexigenic peptides such as GLP-1 [8].  Several types of 
neurons in the LHA also respond to leptin and have been shown to interact with the mesolimbic system to regulate 
motivation and reward, including food reward [9-11]. Thus, Leptin have multiple ways to affect feeding and appetite via 
the brain.  
An obese phenotype is seen when the leptin system is attenuated or fully disrupted. Recessive mutations in either the ob 
gene, encoding functional Leptin, or the db gene encoding the receptor, result in obesity and diabetes in a state 
resembling human obesity [12, 13]. While these genetic alterations are occasionally seen in humans it appears that the 
changed environment, not altered genetics, underlies the ongoing obesity epidemic [14]. An often used research model of 
obesity is the diet-induced obesity (DIO) model which mirrors the high availability of highly palatable calorie-dense foods 
in modern societies. In this model, animals remain lean when maintained on standard chow, but increase their caloric 
intake and rapidly gain adipose mass when given a calorically dense diet [14].  The high-fat diet and related obesity are 
associated with increased serum leptin levels and leptin resistance [15].  
As leptin is important for controlling energy balance it is attractive to imagine leptin as a pharmaceutical treatment option 
for people with obesity. In lean mice administration of leptin by injection or constant subcutaneous infusion results in a 
dose-dependent decrease in body weight within the physiological range of leptin levels [16,17]. Treatment with leptin is 
however ineffective as a way to decrease food intake and body weight in obese individuals [18]. To investigate why 
exogenous leptin treatment does not have the same effect in the obese individuals as in lean individual we in this paper 
focus on brain activation in response to leptin treatment. The brain activation was studied based on detection of pSTAT3 
which is commonly used as a marker of LepRb signalling [19] as it is part of the intercellular signalling occurring in 
response to activation of LepRb. 
Previous work has shown that high fat diet attenuates leptin signalling in the brain [20, 21]. In this paper we pursue this 
hypothesis using novel techniques within imaging and automated quantification. Whole mouse brains were stained to 
visualize LepRb or pStat3 and subsequently scanned using Light Sheet Fluorescence Microscopy (LSFM). Automated 
quantification was performed using a digital brain atlas based on the Common Coordinate Framework version 3 (CCFv3) of 
the Allen Institute of Brain Science. We used these tools to evaluate the LepRb location, the time cause of pStat3 
activation to exogenous leptin, as well as changes in pStat3 response to exogenous leptin in lean mice, DIO mice, and 
db/db mice. No activation was seen in the db/db mice, while the dynamic in brain activation with exogenous leptin was 
lost in the DIO model. The difference in dynamic between lean and DIO was partly explained by a stronger response to 
exogenous leptin in lean mice, but also by larger baseline activation from endogenous leptin in the DIO model. 
 
Results 
The leptin receptor is distributed widely throughout the mouse brain. To investigate the range of brain regions where 
leptin can have a direct effect we generated a 3D map of LepRb expression in the entire mouse brain We used the genetic 
model described by Patterson et al [5], as no sensitive method for LepRb detection by immunohistochemistry (IHC) is 
currently available. The model expresses cre recombinase from the LepRb-specific mRNA in combination with a cre-
inducible enhanced green fluorescent protein (EGFP) to detect the soma of cells expressing LepRb mRNA. The LepRb
EGFP
 
mouse brain was scanned using LSFM to image the whole brain in 3D. The leptin receptor distribution was broad and 
scattered throughout the mouse brain (Fig. 1a-b). Higher concentrations of receptor were seen in cortical regions, 
hypothalamic regions, midbrain regions and hindbrain regions. Cortical regions included Dorsal auditory area (AUDd), 
Supplemental somatosensory area (SSs), and Ectorhinal area (ECT). Hypothalamic regions included Arcuate hypothalamic 
nucleus (ARH), Dorsomedial nucleus of the hypothalamus (DMH), and Lateral hypothalamic area (LHA). Midbrain regions 
included dorsal nucleus raphe (DR), Periaqueductal gray (PAG), and Ventral tegmental area (VTA). Hindbrain regions 
included Parabrachial nucleus (PB), Nucleus of the solitary tract (NTS), and Dorsal motor nucleus of the vagus nerve 
(DMX). In total 49 brain regions were chosen for further studies of pStat3 response (Table 1). 
Figure 1 I Brain regions expressing LepRb. (a) Maximum intensity projection of LepRb
EGFP
 mouse brain. Stongest LepRb expression 
was seen in the hypothalamus (white arrow). (b) Selected 2D coronal projections from (a) showing LepRb in ARH, VMH, LHA, EPd, SSs, 
VTA, SNc, DG, AUDd, SCm, PB, and DMX.  
 
 
Table 1. Selected brain regions with leptin receptor expression 
ACB AI ARH AUDd BMA BST CLA CLI CUN DG DMH DMX DR ECT 
EPd IC IPN LH LHA LPO LRNm LS MEA MEPO MM MPN MTN NTS 
PAG PB PH PMv PRC PRNr PSTN PVH PVp RN SCH SCs SNc SNr 
SSs SUM  TEa TU VMH VTA ZI 
       
The pStat3 response following peripheral leptin dose in general peaks after 1-2 hours. Before evaluating the differences 
between pStat3 activation in disease models, it was important to establish the time lines of such activation. Following 
peripheral administration of leptin animals were euthanized after 10 minutes, 30 minutes, 60 minutes, 120 minutes, and 
240 minutes. The brains were extracted and imaged using LSFM following IHC staining for pStast3 (Fig 2a). Heat maps 
representing the number of cells positive for pStat3 was created and quantified using a digital brain atlas based on the 
mouse brain atlas of the Allen Institute of Brain Science (Fig 2b-c). It was observed that the pStat3 response peaked at 
different time points in different brain regions, although most activation peaked between 60 minutes and 120 minutes 
(Fig 3.a). The earliest peaks (30 minutes) were seen with ARH and Periventricular hypothalamic nucleus, posterior part 
(Pvp) (Fig 3.b). The activation of most other hypothalamic nuclei peaked between 60 minutes and 120 minutes (Fig. 3c-d). 
Activation in the hindbrain peaked between 30 minutes and 60 minutes, while activation in VTA peaked at 240 minutes. 
pStat3 activation in brain regions associated with the limbic system such as the VTA, SNc, and NAc was in general low or 
undetectable. 
 
Figure 2 I Time course of pStat3 activation following leptin dose. (a) Maximum intensity projections of raw pStat3 data in 
mouse brains at different time point after subcutaneous leptin dose. Arrow indicates the hypothalamus. (b-c) Heat map indicating 
number of positive pStat3 cells overlaid onto 2D projections of the Allen mouse brain atlas. Selected brain regions are highlighted to 
show change in activation over the time points.
 Figure 3 I Time course quantification. (a) Heat map showing the level of pStat3 activation in 49 brain regions with LepRb 
expression. The columns represent mouse brains with pStat3 activity measured at different time points after subcutaneous leptin dose. 
Heat map is clustered by rows and columns using a one minus Pearson correlation metric. Baseline pStat3 activation is displayed by 
including vehicle injected animals (columns marked by black line in top and bottom of heat map).  The largest cluster of regions are 
hypothalamic nuclei (marked by black box) displaying peak activation from 30 minutes to 120 minutes. (b-d) Graph showing the mean 
fold change and standard deviation (SD) of the total fluorescence from pStat3 activation as a function of time since leptin dose, n=3-5. 
ARH and PVp activation peaks 30 minutes after leptin dose. 
  
The pStat3 dynamic to peripheral leptin dose is lost in DIO mice compared to lean mice. We next sought to investigate 
potential differences in brain activation to exogenous leptin in normal mice compared to disease models. db/db mice were 
included as these lacks a functional LepRb and should thus show no activation when visualized by pStat3. DIO mice were 
included as this model shows a degree of leptin resistance and best mimics the human obesity epidemic partly driven by 
easy access to highly palatable foods. Brain activation by pStat3 was evaluated 60 minutes after subcutaneous leptin 
injection. Vehicle injections were included to show the pStat3 activation by endogenous leptin levels. As expected no 
pStat3 activation was observed in db/db following either leptin or vehicle injection (Fig. 4a). The only exception was signal 
in Nucleus ambiguus which was seen in all experiment groups. The lean mice showed strong brain activation following 
leptin injection and low activation following vehicle injection. The activation was most prominent in the hypothalamic 
regions. The DIO mice showed an attenuated response to leptin and higher baseline activation compared to lean mice. 
Average heat maps representing the number of cells positive for pStat3 was computed to visualize the difference between 
DIO and lean (Fig. 4b). Quantification of the pStat3 response in eight hypothalamic regions showed a large dynamic in the 
lean model with fold changes ranging from 6.35 (ARH) to 285.06 (LHA) (Fig. 5a). This increase in brain activation from 
exogenous leptin was not seen in the DIO model where the largest fold change was modest 2.66 (PH) (Fig. 5b). The 
difference in pStat3 dynamics between lean and DIO was partly explained by a stronger response to exogenous leptin in 
lean mice (Fig. 5c), but also by a larger activation from endogenous leptin in the DIO model (Fig. 5d). 
 
 
Figure 4 I Comparison of pStat3 activation following leptin dose in different animal models. (a) Maximum intensity 
projection of pStat3 activation in mouse brains following leptin or vehicle dose. (b) Maximum intensity projection of heat maps of 
average pStat3 activation in lean and DIO mice following leptin or vehicle dose, n=4. Heat maps are overlaid onto an auto-fluorescence 
based mouse brain template.  
 Figure 5 I Quantification of hypothalamic pStat3 response (a) Bar graph showing the mean fold change and SD between pStat3 
activation following leptin vs vehicle dose in lean mice. Note the log scale on the y-axis. An asterisk marks significant difference between 
treatments when analyzed in individual brain regions using a false discovery rate value of 5% to correct for multiple comparisons. (b) 
Fold change between pStat3 activation following leptin vs vehicle dose in DIO mice. (c) Fold change between pStat3 activation following 
leptin dose in lean vs DIO mice. (d) Fold change between pStat3 activation following vehicle dose in lean vs DIO mice.  
Discussion 
LepRb expression was detected in various regions throughout the mouse brain with the highest concentration in the 
hypothalamus. Based on the receptor mapping leptin has the ability to directly affect both homeostatic feeding, meal 
generated signals, and reward driven feeding as LepRb was detected in regions such as ARH, LHA, VTA, PB, DMX, and NST. 
The receptor mapping was performed using a genetic model expressing EGFP driven by LepRb-specific mRNA. The EGFP 
accumulates in the cytoplasm and hence show the soma of the neurons containing LepRb mRNA serving as a good 
indicator of where the final receptor is expressed.  However, when detecting the receptor based on mRNA it is possible 
that the receptor is expressed on additional cells or on axons or synaptic cliffs. This was e.g. recently showed in connection 
with GLP-1R [paper under submission / Paper B of thesis]. Better antibodies against the LepRb are needed to further 
clarify this potential issue. 
pStat3 is a commonly used marker for LepRb activation and a time course study was performed to investigate the 
activation following a subcutaneous leptin dose. After 10 minutes, the earliest time point studied, the most significant 
pStat3 activation was seen in the ARH and PVp. This result fits with observations made by Ballard et al [22] describing 
tanycytes in the median eminance as the earliest access point of peripheral leptin to the brain. From ME leptin could reach 
the ARH and other hypothalamic regions. In this study we also observed increased pStat3 activation in DMX after 10 
minutes suggesting signalling through the vagal nerve. After 30 minutes pStat3 activation was seen wide spread, including 
deeper regions such as LHA and PB. In general the pStat3 activation was strongest at the 60 minutes and 120 minutes time 
point which can be concluded to be suitable for studying activation of peripheral administrated leptin. Looking across the 
time points not all regions with LepRB was activated. As an example no activation was detected in the cerebral cortex, but 
also regions connected to the limbic system such as VTA, SNr and NAc showed at best very sparse signalling. This suggests 
that the effects of peripheral administered leptin mostly occur through the hypothalamus and hindbrain, but could also be 
through midbrain regions such as DR, PAG, and SCm which also displayed prominent pStat3 response. Concerning the 
methodology applied in these studies we utilized LSFM in combination with whole brain IHC staining using the iDISCO 
protocol [23]. With this system different positively stained cells may have different levels of intensity. The heat maps 
computed for the individual brains only reflect the number of positively stained cells, but not the absolute intensities of 
these cells. An example of this is seen in figure 2a where the absolute intensities are in general stronger after 60 minutes 
compared to 120 minutes. However, in regions where the number of positively stained cells is slightly higher after 120 
minutes the computed heat maps are also more intense at the 120 minute time point. A 60 minute time point was chosen 
to study the pStat3 response in lean versus obese animal models. 
pStat3 activation was next compared after leptin or vehicle dosing in different animal models to investigate why 
exogenous leptin has not shown to be an efficient treatment for obesity. No activation was seen in the obese db/db 
phenotype as expected since the mice lack a functional LepRb. Pstat3 activation in lean mice showed a large response to 
exogenous leptin, and could explain why administration of leptin by injection results in decrease in body weight as 
previously reported [16,17]. On the contrary pStat3 activation in the hypothalamus of DIO mice showed no increase of 
pStat3 activation in leptin versus vehicle dosed animals. In essence this means that the leptin injection was redundant as it 
did not change the brain activation compared to the baseline condition probably driven by high levels of endogenous 
circulating leptin. A similar picture was seen in the DMX and NTS of the hindbrain. Similar findings were reported by 
Morabito et. al. [20] comparing the dynamic of the pStat3 response in mice on low fat or high fat diet. In that study some 
of the mice on high fat diet was later switched to low fat diet after which they returned to a body weight comparable to 
the original low fat group. Following this intervention the pStat3 dynamic in the NTS was recovered, but not the dynamic 
in ARH and DMH.  Pablo et al. [21] studied the effects of leptin on AgRP and NPY secretion comparing lean and DIO mice. 
Incubation with leptin caused dose-dependent inhibition of AgRP and NPY in lean mice but not in DIO. Similar results were 
obtained looking at the sensitivity of POMC neurons by measuring levels of α-MSH. Again the sensitivity to leptin was lost 
in the DIO group.  This could suggest that while pStat3 activation was still seen in ARH of the DIO mice in our study the 
downstream effects from the LepRb activation could still be lost. In the study by Pablo et al. [21] the sensitivity to leptin 
was restored after switching the mice from high fat diet to chow and allowing them to return to a body weight 
comparable to the original lean group. In general DIO animals tend to reduce their food intake and body weight when 
switched to a less palatable diet and this suggests that the DIO mice do not eat to defend a new homeostatic set point, but 
rather they eat because of the pleasure from the reward associated with a calorie-dense diet. Part of the explanation why 
high levels of circulating leptin do not mitigate the high calorie intake could be that the leptin effect on the limbic system 
is low. In our study the direct activation based on pStat3 was low in the limbic system. The limbic system could however 
still be activated as secondary effects of e.g. the LHA as discussed in the review by Myers et. al [24]. Despite what the 
underlying mechanisms are, either way leptin is not a good treatment for obesity as it provides little additional 
information to the brain compared to baseline conditions. 
 
Methods 
Animals. All in vivo studies were conducted in accordance with approved national regulations in Denmark, which are fully 
compliant with internationally accepted principles for the care and use of laboratory animals, and with animal 
experimental licenses granted by the Danish Ministry of Justice. Animals were obtained from Taconic, Denmark and 
housed in standard, temperature-controlled conditions with a 12-hour-light/dark cycle. The animals had ad libitum access 
to water and regular chow. 
Whole brain pStat3 staining. C57Bl/6J male mice were subcutaneously injected with leptin (3 mg/kg) or vehicle (n=5). 
Mice were euthanized 60 min. (disease model study) or 10 min., 30 min., 60 min. 120 min., 240 min. (time course study) 
after injection using isofluorane followed by cardiac perfusion with 4% paraformaldehyde.  Brains were excised and post 
fixed in 4% paraformaldehyde overnight at room temperature and transferred stepwise to 100% methanol using the 
following protocol. 20% methanol (in ddH2O) for 1h, 40% methanol for 1h, 60% methanol for 1h, 80% methanol for 1h, 
and 100% methanol for 1h twice. iDISCO staining was performed as described in Renier et al.[19] with one exception. All 
the washing steps after incubation with primary and secondary antibody were extended from one to three days. 
Incubation time for primary and secondary antibody was 4 days each. The primary antibody was Rabbit-a-pSTAT3 (#9145) 
from Cell Signaling (1:500 dilution), and the secondary antibody was Cy5-anti rabbit from Jackson Immunoresearch 
(1:1000 dilution). 
Light sheet imaging. Brain samples were scanned using an UltraMicroscope II LSFM system (Lavision Biotec, Bielefeld, 
Germany) in 4.06 μm isotropic resolution. Data acquisition was performed using a 545 nm emission filter for imaging auto-
fluorescence, and a 620 nm emission filter for imaging specific signals. 
Image analysis. Images were registered to the digital brain atlas using the Elastix software library [25]. A source image IS(x) 
was registered to a target image IT(x) by finding a coordinate transformation T(x) that made IS(T(x)) spatially aligned with 
IT(x). We used an affine coordinate transformation for initialization followed by non-rigid b-spline coordinate 
transformation which was iteratively optimized with respect to the mutual information between the source and the 
target. Registration parameters for mapping of LSFM data were similar to those used in Renier et al.
3
. Cells segmentation 
of cells positive for pStat3 was performed using a combination of blob filtering and morphological operations. Heat maps 
were created by summing uniform intensity discs with diameter of 20 um placed on each voxel representing a cell.  The 
algorithms were written in Matlab (Release 2012b, MathWorks, Natick, Massachusetts, United States) and applied as a XT-
plugin in Imaris (Release 7.6.5, Bitplane, Zurich, Switzerland). These software programs were also used to generate all 
figures in the manuscript. 
Statistical analysis. ROI based analyses of the total fluorescence signal presented in Fig. 5a-d were computed using 
multiple t-tests assuming unequal variance. Statistical significance was determined by correcting for multiple comparisons 
using a false discovery rate set to 5%. The statistical analysis was performed using Graphpad Prism (Release 6, GraphPad 
Software, Inc., United States). 
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ABSTRACT
Active Appearance Models (AAM) are used for annotating or seg-
menting shapes in biomedical images. Performance relies heavily
on the image data used to train the AAM. In this paper we im-
prove the generalization properties of the model by making it ro-
bust to slowly varying spatial intensity inhomogeneities which are
often seen in Light Sheet Fluorescence Microscopy (LSFM) images.
This robustness is achieved by modelling the appearance of an im-
age as a regularized Normalized Gradient Field (rNGF). We perform
two experiments to challenge the model. First it is tested using a
repeated leave-one-out approach on images with minimal imperfec-
tions where the left out images are corrupted by a simulated bias
field and segmented using the AAM. Secondly we test the model
on LSFM images with common acquisition problems. In both ex-
periments the proposed approach outperforms the often used AAM
implementation based on Sum of Squared Differences.
Index Terms— Active Appearance Model, regularized Normal-
ized Gradient Field, Light Sheet Fluorescence Microscopy, Segmen-
tation
1. INTRODUCTION
Light Sheet Fluorescence Microscopy (LSFM) is an imaging tech-
nology for studying biology on a microscopic scale. The technology
has for instance been used to image whole mice brains with micro-
meter resolution [1]. A scan sequence can acquire multiple contrasts,
recording auto-fluorescence of the tissue in one channel and specific
fluorescently labelled proteins in an other. With auto-fluorescence
providing anatomical information, and the labelled protein revealing
function, LSFM is of broad interest for mode of action studies both
in basic as well as applied research.
To fully utilize the potential of the modality requires a segmen-
tation of anatomical regions which is particularly challenging due to
image distortions affecting both intensities and shape anatomy. In
animal studies the anatomic distortions may be caused by brain ex-
traction and chemical tissue clearing, which are performed prior to
scanning and allows the light sheet to penetrate with minimal scat-
tering and absorption [2]. The tissue clearing procedure also intro-
duces unwanted intensity distortions since the efficiency varies be-
tween subjects. The optical elements inside the LSFM system also
causes intensity distortions which may appear differently across sub-
jects but generally appear as slowly varying spatial inhomogeneities
of the intensities.
These distortions pose a challenge to image segmentation meth-
ods. The most common form of LSFM-related segmentation con-
cerns the identification of highly local intensity build ups [3], used
to investigate cellular morphologies within anatomical regions of in-
terest. For high-throughput studies, manually delineating anatomic
regions becomes in-feasible. Recent work in mice has used atlas-
based segmentation methods to address this issue. For instance, we
[4] previously performed segmentation using image registration to
transform labels from a digital mouse brain atlas towards an individ-
ual mouse.
In this work we developed a model for segmentation based on
the Active Appearance Model (AAM) [5], a model known to have
problems dealing with varying illuminations across an image pop-
ulation [6]. Within the area of face recognition, robustness against
illumination is typically achieved by normalizing intensity appear-
ance [7],[8]. In our approach, this normalization is achieved by ex-
tending the AAM to model the textural appearance given as a reg-
ularized Normalized Gradient Field (rNGF) [9]. The idea is sim-
ilar to using that of [7] aimed at facial recognition. Instead of a
simple gradient field, we use a regularized version combined with
a different optimization strategy for fitting the model to new im-
ages. It leads to a model that is robust to noise and has invariance
with respect to the slowly varying intensity distortions present in the
LSFM modality. To our knowledge it is the first time the AAM has
been adopted toward LSFM images. We successfully demonstrate
the rNGF-based AAM in two experiments on acquired images of
the c57bl mouse brain. It is first demonstrated for the purpose of
segmenting five anatomical brain regions in images which were ar-
tificially corrupted by a user controlled bias field. Secondly the ap-
proach is demonstrated on data exhibiting common LSFM artefacts.
2. DATA
2.1. Tissue preparation and data acquisition
All in vivo studies were conducted in accordance with approved na-
tional regulations in Denmark which are fully compliant with in-
ternationally accepted principles for the care and use of laboratory
animals, and with animal experimental licenses granted by the Dan-
ish Ministry of Justice. After sedation the mice were euthanized by
cardiac perfusion with heparinized (10U/ml) saline followed by 10%
neutral buffered formalin (NBF). The brains were removed and im-
mersed into 10% NBF and stored at 4◦C until further processed. The
brains were cleared for LSFM by a stepwise dehydration and clear-
ing process using tetra-hydro-flurane and di-benzyl-ether (DBE), re-
spectively [2]. Data acquisition was performed with a dual side il-
lumination Ultamicroscope using a SuperK white light laser, and an
Andor Neo sCMOS camera. The images were acquired in 10.32 µm
isotropic resolution.
2.2. Shape annotation of images
After acquisition the brain volumes were transformed to a standard
space using rigid registration. For the purpose of building the AAM,
a coronal slice corresponding to the same anatomy across subjects
was selected for manual annotation. The five regions of annotations
were; Lateral Ventricle (VL), Zona Incerta (ZI), Spinal Nucleus of
the Trigeminal, caudal part (SPVC), Dentate Gyrus, part 1 (DG 1),
and Dentate Gyrus, part 2 (DG 2), see Fig. 1, top. The shapes of
these regions were annotated using 4, 4, 4, 6 and 5 anatomic land-
marks respectively. As a final preprocessing each shape was equidis-
tantly up-sampled to consists of 40 coordinates yielding a total of
200 correspondence points per image.
3. METHOD
The method used for segmenting LSFM images is based on the
AAM [5]. This is a generative model of both shape and appearance
(image texture). In the following sections it is explained how we ex-
tend the AAM to obtain improved LSFM segmentation performance.
First we introduce the rNGF as a descriptor of image appearance.
This descriptor is suitable for LSFM images as it has a built-in
invariance against slowly varying spatial intensity inhomogeneities.
Next follows a section detailing how to estimate the model, and the
final section explains how this model was made active, enabling it
to segment new images.
3.1. Texture: The regularized Normalized Gradient Field
The most common way of describing appearance is using pixel in-
tensities. Appearance models based on intensities work well in many
circumstances but have difficulties coping with intensity distortions
not previously seen by the model. To achieve invariance against such
distortions our appearance will be based on the rNGF as proposed by
Haber [9]
n(I(x)) =
∇I(x)√∇I(x)T∇I(x) + 2 ,  = ηV
∫
Ω
|∇I(x)| ∂x.
(1)
The rNGF in n(I(x)) maps the image I(x) to a higher dimensional
space where the texture at pixel position x is mapped to a directional
vector with elements in the range n ∈ [0, 1]. To control the im-
pact of noise, the value of  is set by summing the absolute image
gradients across the domain Ω, dividing with the image area V, and
multiplying by η. Thus η effectively controls  and since n → 0
for ∇I(x)T∇I(x) << 2, it determines when an image gradient is
considered noisy.
3.2. The Appearance Model
Appearance Models [5] establish a compact parameterization of ob-
ject variability, as learned from a training set of shape and texture.
The shape of each training image is defined by N = 200 manu-
ally placed landmarks as previously explained. The shapes of these
training subjects are aligned to a common mean using the Gener-
alised Procrustes Analysis (GPA) [10] removing effects of transla-
tion, rotation and scaling. Similarly, the textures of the training im-
ages are warped into the cross-correspondence mean shape space
using a piece-wise affine warp. The obtained intensity textures are
sampled and mapped to the rNGF representation. Shape and texture
variability models are now formed based on the eigenvectors of the
Nd×Nd shape covariance matrix and the dK×dK texture covari-
ance matrix respectively. Here d is number of image dimensions, N
is the number of landmarks used to represent each shape and K is
the number of intensities sampled for each training example. The
individual shape and texture models are
x = x¯+ Φxbx, g = g¯ + Φgbg (2)
Where x denotes the column form of a modeled shape, x¯ is the train-
ing shape mean, Φx and bx correspond to the shape eigenvectors and
parameters respectively. Similarly, rNGF texture is modeled by g,
the texture mean (g¯), the eigenvectors (φg) and the parameters (bg).
A combined shape and texture model is made by concatenating the
parameters of bx and bg for all training examples and performing
and additional eigen-decomposition. This gives the model
x = x¯+ ΦxW
−1
x Φc(x)c, g = g¯ + ΦgΦc(g)c, (3)
where c is a vector containing the model parameters affiliated with
the eigenvectors in matrices Φc(x), Φc(g) given by the sub-matrices
of Φc, corresponding to rows related with shape and texture respec-
tively. The matrix Wx is a diagonal matrix weighting which ac-
counts for unit differences between shape and texture. These weights
are estimated by perturbing the shape parameters of all training data
by one unit and measuring the average euclidean change in texture.
To get a regularized model, the eigenvectors explaining least
training variability are removed from the model using the 95% cri-
teria [11]. An example of the principle variability captured by such
a model is shown in Fig. 1. By varying the first parameter of the
model, it appears the dominant shape variability is cause by size and
the between shape positioning of the five shapes. The first parameter
of the rNGF appearance is more difficult to interpret but seems to be
related with gradient magnitudes.
3.3. Model-based segmentation
Fitting the rNGF-based AAM to a new image requires minimization
of a cost function measuring discrepancies between the rNGF image
texture n(I(x)) and the model texture g(x)
C(c, S) =
∫
Ω
||n(T−1(I(S(x))))− g(x)|| ∂x. (4)
The brackets || ∗ || refers to the Euclidean norm and T−1 describes
the texture mapping from the image to the normalized model space,
achieved using a piece-wise affine warp. The cost function is min-
imized with respect to two parameters. The AAM parameters in c,
and the parameter S which describes a global similarity transforma-
tion given by 4 parameters (scale, rotation and two translations).
Optimization details
The parameters are estimated using a gradient descent algorithm [12],
where numeric gradients are obtained from a central finite differ-
ence approximation. To avoid local minima this is done with a
multi-resolution strategy using 4 resolution levels, each resolution
optimized and propagated in a coarse to fine manner.
The starting guess for the optimization is the mean model and
the same optimization is run 9 times with different spatial starting
positions. The 9 positions include the image centroid and 8 regu-
larly sampled positions around the center. At the end of this grid
search the fit with lowest cost function value in equation (4) is kept
as optimal.
To prevent the AAM model parts composed of low magnitude
gradients from fitting to the background, intensities are artificially
inserted into the background of the intensity images prior to fitting.
These values are inserted using an alternating 2 × 2 checkerboard
pattern, set to either plus or minus the maximum image intensity.
Fig. 1. Examples of two LSFM images overlaid with the shape an-
notations of VL, DG 1, DG 2, ZI and SPVC. The combined shape
and appearance model built from 21 subjects is illustrated by setting
the first parameter of equation (3) to ± 3 standard deviations of the
associated eigenvalue. Magnitudes of the rNGF fields are indicated
by the [0,1] color-bar. Dimension of the images is 700x957 pixels.
4. RESULTS
To show the increased robustness of using rNGF-based segmentation
in LSFM images, two experiments were performed. The first exper-
iment investigated the effect of manipulating the images by applying
a controlled artificial bias field to mimic slowly varying spatial inten-
sity inhomogeneities. The Dice score [13] was used to evaluate the
quality of the segmentation. Evaluation of the AAM was performed
using a leave-one-out cross validation approach based on 21 mouse
brains. The brains were acquired as uniformly as possible regarding
optical parameters and tissue clearing.
Fig. 2. A: Images of selected artificial generated bias fields and the
effect of applying these to the test images. The bias field parameter
value used to generate the specific bias fields are displayed above the
images. B: Top plot shows the overall Dice scores (mean value and
standard deviation) of the two models as function of the applied bias
field strength. Bottom plot shows the Dice scores of the individ-
ual annotation structures. The rNGF-based results are shown with
dashed lines, and SSD-based results are shown with dotted lines.
The left-out test images were systematically corrupted by multi-
plication with artificially generated bias fields of increasing strength,
see Fig. 2.A. The bias fields were constructed using a Gaussian ker-
nel with the bias field parameter corresponding to the percentage-
wise decrease in pixel intensities towards the border of the images.
The overall Dice score of the model as function of the bias field
strength is seen in Fig. 2.B, top plot. A bias field parameter equal
to zero means that no bias field distortion was applied to the images.
The Dice scores of the individual anatomical shape segmentations
are seen in Fig. 2.B, bottom plot. Annotation names and line color
match those seen in Fig. 1. The rNGF-based model performs on par
or better for all cases compared to the AAM implementation based
on Sum of Squared Differences (SSD).
The second experiment investigated the model performance un-
der a more realistic scenario. The AAM trained on the 21 brains from
the first study was tested on images with common LSFM imperfec-
tions. The test set consisted of 8 images where half contained brains
with poor tissue clearing and the other half contained brains scanned
with a lower quality light sheet. Examples of segmentation results
obtained with the rNGF-based AMM and the SSD-based AAM are
seen in Fig. 3.A. The SSD-based model fails to segment the VL in
case of the lower quality light sheet. Dice scores of the individual
annotation structures are seen in Fig. 3.B. The rNGF-based model
results in higher Dice scores and less variance.
Fig. 3. A: Examples of segmentations obtained with rNGF-based
model (top row) and SSD-based model (bottom row). Left image
shows a brain with poor tissue clearing and right image shows a brain
recorded with lower quality light sheet. B: Boxplot of Dice scores
of the individual annotation structures. The median is represented as
the center line of each box and the edges correspond to the 25th and
75th percentiles.
5. DISCUSSION
In contrast to the classical SSD-based model, the rNGF-based AMM
is robust to artificial image corruption by a controlled bias field. The
rNGF-based model shows only slight performance decrease when
tested on images distorted with more extreme bias fields (Fig. 2.B,
top plot). Even with the largest image distortion, the model provides
a good result with a Dice score close to 0.8 whereas the SSD-based
implementation breaks down completely. This result is seen for all
annotation structures (Fig. 2.B, bottom plot) which confirms that the
regularized normalized gradient measure is less affected by slowly
varying spatial intensity inhomogeneities.
The rNGF-based model also generalizes well to images with
lower quality compared to the training set (Fig. 3.B). The test set
contains images obtained with a lower quality light sheet making
the images appear blurry, and of images of brains with poor tissue
clearing causing a different intensity distribution. Both challenges
are handled by the rNGF-based model showing the promise of this
model for segmentation of LSFM images. The rNGF-based model
performs well for structures having large gradients to surrounding
tissue such as the VL (blue), but also for structures where the gra-
dients are smaller and more specular such as the Zona Interna (red)
and SPVC (pink).
In summary we have shown that the rNGF-based AAM is ro-
bust to effects of poor tissue clearing and to variation in quality
of the light sheet used during image acquisition. Having a model
for robust segmentation of anatomic regions shows promise for con-
ducting automated high-throughput studies of the mouse brain using
LSFM.
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Appendix F
List of brain regions
ACB Nucleus accumbens
AHN Anterior hypothalamic nucleus
AOB Accessory olfactory bulb
AP Area postrema
ARH Arcuate hypothalamic nucleus
AUDd Dorsal auditory area
BLA Basolateral amygdalar nucleus
BMA Basomedial amygdalar nucleus
BST Bed nuclei of the stria terminalis
CA1 Field CA1
CA2 Field CA2
CA3 Field CA3
CEA Central amygdalar nucleus
COA Cortical amygdalar area
CU Cuneate nucleus
DG Dentate gyrus
DMH Dorsomedial nucleus of the hypothalamus
DMX Dorsal motor nucleus of the vagus nerve
DR Dorsal nucleus raphe
ECT Ectorhinal area
ECU External cuneate nucleus
GENd Geniculate group, dorsal thalamus
GR Gracile nucleus
132 List of brain regions
IC Inferior colliculus
LC Locus ceruleus
LH Lateral habenula
LHA Lateral hypothalamic area
LPO Lateral preoptic area
LRNM Lateral reticular nucleus, magnocellular part
LS Lateral septal nucleus
LSc Lateral septal nucleus, caudal part
ME Median eminence
MEA Medial amygdalar nucleus
MEPO Median preoptic nucleus
MH Medial habenula
MM Medial mammillary nucleus
MPT Medial pretectal area
MRN Midbrain reticular nucleus
MTN Midline group of the dorsal thalamus
NI Nucleus incertus
NLL Nucleus of the lateral lemniscus
NTS Nucleus of the solitary tract
OV Vascular organ of the lamina terminalis
PAG Periaqueductal gray
PB Parabrachial nucleus
PCG Pontine central gray
PG Pontine gray
PH Posterior hypothalamic nucleus
PMv Ventral premammillary nucleus
PSTN Parasubthalamic nucleus
PVH Paraventricular hypothalamic nucleus
PVp Periventricular hypothalamic nucleus, posterior part
PVT Paraventricular nucleus of the thalamus
RE Nucleus of reunions
RHP Retrohippocampal region
SCH Suprachiasmatic nucleus
SCm Superior colliculus, motor related
SF Septofimbrial nucleus
SFO Subfornical organ
SNc Substantia nigra, compact part
SNr Substantia nigra, reticular part
SO Supraoptic nucleus
SPVC Spinal nucleus of the trigeminal, caudal part
SSs SSupplemental somatosensory area
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TTd Taenia tecta, dorsal part
TU Tuberal nucleus
V4 fourth ventricle
VL lateral ventricle
VMH Ventromedial hypothalamic nucleus
VTA Ventral tegmental area
ZI Zona incerta
134 List of brain regions
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